

Implementing essential diagnostics-learning from essential medicines: A scoping review

Authors:

Moriasi Nyanchoka ^{1*}, Mercy Mulaku ^{1,2,3}, Bruce Nyagol ¹, Eddy Johnson Owino ¹,
Simon Kariuki ¹, Eleanor Ochodo ^{1,2}

Authors Affiliation:

¹ Centre for Global Health Research, Kenya Medical Research Institute, Kenya

² Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics,
Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa

³ Department of Pharmacy, Faculty of Health Sciences, University of Nairobi, Kenya

Declaration of interests: None declared

* moriasi.nyanchoka@outlook.com

Abstract

Background: The World Health Organization (WHO) model list of Essential In vitro Diagnostic (EDL) introduced in 2018 complements the established Essential Medicines List (EML) and improves its impact on advancing universal health coverage and better health outcomes. We conducted a scoping review of the literature on the implementation of the WHO essential lists in Africa to inform the implementation of the recently introduced EDL.

Methods: We searched eight electronic databases for studies reporting on the implementation of the WHO EDL and EML in Africa. Two authors independently conducted study selection and data extraction, with disagreements resolved through discussion. We used the Supporting the Use of Research Evidence (SURE) framework to extract themes and synthesized findings using thematic content analysis. We used the Mixed Method Appraisal Tool (MMAT) version 2018 to assess the quality of included studies where applicable.

Results: We included 172 studies reporting on EDL and EML after screening 3,813 articles titles and abstracts and 1,545 full-text papers. Most (75%, n=129) included studies were purely quantitative in design comprising descriptive cross-sectional designs (60%, n=104), 15% (n=26) were purely qualitative, and 10% (n=17) had mixed-methods approaches. There were no qualitative or randomised experimental studies about the EDL. The main barrier facing the EML and EDL was poorly equipped health facilities - including unavailability or stock-outs of essential in vitro diagnostics and medicines and inadequate infrastructure to enable health service delivery. Financial and non-financial incentives to health facilities and workers were a key

enabler to the implementation of the EML however, their impact differed from one context to another. Fifty-six (33%) of the included studies were of high quality.

Conclusions: The EDL implementation at the national level can learn from health system interventions to improve the availability and supply of essential medicines such as financial and non-financial incentives in different contexts.

Keywords: *Essential In Vitro Diagnostic Lists, Essential Medical Lists, Essential Diagnostics, WHO Essential Lists, Africa, Scoping Review*

Plain language summary

The World Health Organization (WHO) periodically publishes the Model lists of essential medicines (EML) and essential in vitro diagnostics (EDL) to offer guidance to member states. The model lists help countries prioritise the critical health products that should be widely available and affordable throughout health systems. Countries frequently use these model lists to help develop their local lists of essential medicines and diagnostics. The model list of essential diagnostics was introduced in 2018, while the essential medicines were introduced 45 years ago. This work evaluates current evidence on the implementation of the more established model list of essential medicines to inform the development and implementation of the national list of essential in vitro diagnostics in Africa.

We reviewed results from all available studies that looked at the provision of treatment and/or diagnostic services in Africa and assessed the barriers and enablers for their implementation.

We found 172 articles assessing the provision of treatment and diagnostics in Africa. We looked in detail at the barriers and enablers to implementing the model lists of essential medicines and essential in vitro diagnostics. We also assessed the quality of the included research studies. We combined the results of the studies and established that the health system barriers were the most dominant constraints to implementing the model lists.

Our review found the implementation of the established EML, the new EDL was mainly due to poorly equipped health facilities, including limited availability, and stock outs of

essential medicines and tests. It is important to consider these constraints when developing and implementing the EDL at various national levels. EDL Implementation at the national level can learn from interventions to improve the availability and supply of essential medicines. Financial and non-financial incentives may be enabling interventions, but their effect varies in different countries and contexts.

Introduction

Access to diagnostic tests is a key component in achieving Sustainable Development Goals (SDG) 3.8. and Universal Health Coverage (UHC) ^{1,2}. Insufficient access to essential in-vitro diagnostics is a major global health challenge, and nearly half (47%) of the global population have little to no access to diagnostics ³. The scale and scope of this challenge contribute to delay in diagnosis and initiation of appropriate treatment compromising health outcomes, especially in Africa ³⁻¹³.

The World Health Organization (WHO) published the first model list of Essential In Vitro Diagnostics (EDL) in 2018 ¹⁴ to guide the selection and prioritisation of essential diagnostics according to national needs. It complements the WHO Essential Medicines List (EML) and links medicines with diagnostic tests to advance the UHC ^{11,15}. It paves the way toward improved healthcare delivery and ultimately better patient outcomes by promoting greater equitable access to quality and affordable diagnostics at all levels of the healthcare delivery system ¹⁶. To ensure its impact, countries will need to develop national lists that suit their national or regional needs, disease burdens, and health system capacities ^{2,5,17}. To date, three WHO EDL model lists have been published ^{14,18,19}. The first WHO EDL contained 113 tests and was updated by WHO in 2019 to include nine additional tests for non-infectious diseases. The 2020 list had more other tests, including pandemics such as Covid-19.

The WHO published the first EML about 45 years ago, in 1977 ²⁰. This established initiative has been updated biannually since 1977, with the latest 22nd version updated in September 2021 ²¹. Though the adaption of WHO EML to National Essential Medicines Lists (NEMs) has been broad in Africa, numerous challenges continue to

blunt its impact, including persistent inadequate and inequitable access to medicines^{22–25}. Lessons learned in implementing the established WHO EML may shed light on implementation considerations of the WHO EDL and guide the development of practice tools to support the wider adoption of the WHO EDL in Africa.

The objective of this scoping review was to map evidence on the implementation and evaluation of the WHO's essential lists in African countries to guide the effective implementation of the new WHO EDL.

Methods

The protocol of this scoping review is available on Open Science Framework ²⁶ with deviations from the protocol listed in the S1 Appendix.

We conducted this review according to the Joanna Briggs Institute guidelines for scoping reviews ²⁷ and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) ²⁸ checklist recommended for scoping reviews (S1 Checklist).

Information sources

A systematic search of the literature was conducted up to May 2021 without date restrictions. We searched several electronic databases: *Ovid MEDLINE*, *Embase*, *CINAHL*, *Web of Science*, *African Index Medicus*, *Cochrane Central Register of Controlled Trials*, *SCOPUS*, and *Health system evidence* for eligible studies. An example of the search strategies *MEDLINE* can be found in the S2 Appendix. The literature search was complemented by scanning the reference lists of included studies. The references were exported to an EndNote database following the literature search, and the duplicates were removed.

Eligibility criteria

Types of studies

We included EDL studies published in English after introducing the first EDL in 2018. However, given the vast number of studies for the 40-year EML initiative, we included EML studies published in 2010 and after to get a recent representative sample that would inform the implementation of the EDL. If data saturation were not achieved in this sample, we would look to studies published before 2010. We included primary experimental and observational studies and primary qualitative studies. We excluded study protocols, literature reviews, systematic reviews, scoping reviews, book chapters, personal opinions papers, editorials, and conference abstracts with insufficient information. We, however, excluded all conference abstracts and editorials on EML due to the vast number of full-text studies and the high likelihood of data saturation.

We selected eligible studies guided by the Population-Concept-Context (PCC) framework designed by the Joanna Briggs Institute ²⁹, commonly used to focus research questions for scoping reviews as detailed below:

Population

We included articles reporting on the provision of essential medicines and diagnostic tests (as defined by authors or by the WHO Criteria)^{19,21} to human populations. We did not limit our review to any disease condition.

Concept

We included articles that discussed the implementation of the WHO essential lists, defined in our review as the adoption and adaptation of WHO essential lists by individual WHO member states to address national priority healthcare needs and gaps in the health systems. We also included articles that evaluated interventions used to enhance or enable the implementation or uptake of the essential lists.

Context/Settings

We included all studies conducted in all health care settings or levels in Africa. Due to the high likelihood of data saturation, we restricted EML studies to those conducted in single countries. Such studies were likely to give rich data about implementation considerations in one setting or context.

Outcomes

Our outcomes of interest were:

- Types of study designs about the implementation of the EDL and EML.
- Themes about barriers and enablers of EDL and EML.

Study selection

We uploaded references compiled using *Endnote* to Covidence ³⁰, a web-based systematic review software platform. We first screened titles and abstracts for potentially eligible articles and then screened full texts of the articles where available. Independent reviewers (MN, BN, EJO, MM) screened all titles, abstracts, and full-text articles in duplicate for eligibility. We resolved disagreements through consensus in

consultation with a senior reviewer (EO). Articles that met the inclusion criteria following a full-text review were selected for data extraction.

Data extraction

We developed a data extraction form using the google form platform. We piloted it with 10% of the included studies by two reviewers to ensure the accuracy of the form and consistency of the extracted content.

The extracted data included general study information (authors and year of publication and the study title); general study characteristics (the study aim, study type, country of study, study setting, facility type, the study population), and information about barriers and enablers to implementing the essential lists (EDL and EML). We extracted data independently in duplicate (MN, BN, EJO, MM) about themes for barriers and enablers to health systems using the Supporting the Use of Research Evidence (SURE) framework (S2 Appendix) ³¹. We resolved disagreements in data extraction through consensus in consultation with a senior reviewer (EO).

Quality assessment

We assessed the methodological quality of all included studies using the Mixed Method Appraisal Tool (MMAT 2018) ³². The tool is grouped into five categories of study designs: qualitative designs, quantitative randomized controlled trials, quantitative non-randomized, quantitative descriptive, and mixed methods. The appraisal led to an overall methodological quality rating varying from unclassified, 0% (no quality), 20% (low quality), 60% (moderate quality), 80 (considerable quality), and 100% (high

quality) for each study. Not all eligible studies provided sufficient information to appraise quality using the MMAT. A study was categorised unclassified if it was a report or study that did not provide adequate information for MMAT appraisal. Quality ratings were not used to include or exclude studies but instead used to describe the overall quality of evidence of the included studies.

Data synthesis

Thematic content analysis was conducted to chart codes and synthesize themes. We summarized the results descriptively and graphically.

Results

Search results

Our search yielded 3813 records, nine of which were duplicates Fig 1. Of the remaining 3804 citations screened, 2259 did not meet the inclusion criteria. A further 1373 citations were excluded at full text review, as they did not meet the inclusion criteria for full text review based on year of publication (n=523), not focussing on implementation of WHO essential lists (n=324), ineligible article type (n=265), ineligible context (n=102), multi-country studies about EML (n=67), no full text availability (n=52), duplicates (n=21), non-English publication language (n=16), animal studies (n=3).

Characteristics of included studies

We included 172 studies. Four (2.3%) of the studies were on the implementation of EDL, eleven (6.4%) focused both on EDL and EML, and 157 (91.3%) focused only on the EML. Details of the included studies can be found in the appendix (S3 Appendix).

Of the (EDL) studies (n=15), eight (53.3%) were from Eastern Africa, five (33.3%) from Southern Africa, and two (13.3%) from West Africa. Methodologically, twelve (80%) of EDL studies used quantitative methods (cross-sectional designs), and three (20%) used the mixed methods approach (Table 1).

Table 1: Characteristics of Studies about the Essential In Vitro Diagnostics List (EDL)

Category	Details	Number (n)
WHO Essential Diagnostic List (EDL)	Total EDL studies	15
	EDL sole focus	4
	EDL and EML combined	11
Publication year	2018-2021	15
Study Designs	Cross-sectional study	12
	Mixed methods (Quantitative and Qualitative)	3
Disease categories	Communicable diseases	2
	Non-communicable diseases	12
	Combined communicable & non-communicable diseases	1
Populations at risk	Adults	1
	Adults & Children (mixed)	11
	Unclear	3
Type of participants*	Health workers	15
	Patients	3
	Health care managers	2
	Laboratory workers	1
	Other research staff	1
Region*	Eastern Africa (Kenya, Ethiopia, Madagascar, Tanzania, Uganda, Sudan, Rwanda)	8
	Southern Africa (South Africa, Namibia, Malawi, Mozambique)	5
	West Africa (Nigeria, Ghana, Burkina Faso)	2
Type of facility*	Hospitals	10
	Primary health care facilities	7
	Laboratory	2
	Pharmacies/Dispensaries	2
	Unclear	1
Location of health facility	Rural	1
	Urban	4
	Rural and urban	4
	Unclear	6

*Some studies reported more than one detail

Of the EML studies (n=168), eighty-five (51.2%) were from Eastern Africa, forty-five (27.4%) were from Southern Africa, thirty-two (19.0%) were from West Africa, five (3.0%) from Central Africa and one (0.6%) from North Africa (Table 2).

Table 2: Characteristics of studies about the Essential Medicine List (EML)

Category	Details	Number (n)
Essential Medicine List (EML)	Total EML studies	168
	EML focus only	157
	Combined EML & EDL studies	11
Publication year	2010 – 2021	168
Study Designs	Cross-sectional study	100
	Qualitative study	26
	Mixed methods	17
	Cohort study	5
	Randomized controlled trial	4
	Interrupted Time Series	4
	Quasi-Experimental study	1
	Other Experimental designs	2
	Other Descriptive designs	9
Disease categories	Communicable diseases	19
	Non-communicable diseases	51
	Both communicable and non-communicable diseases	51
	Unclear	47
Populations at risk	Children	22
	Adults	16
	Mixed populations (adults and children)	86
	Unclear	44
Type of participants*	Patients	33
	Health workers	129
	Health care managers	31
	Laboratory workers	2
	Community residents	8
	National Essential Lists Committee	15
	Health care stakeholders	13
	Policy document analysis, reviews, Inventory analysis, Ministry officials	15
	Unclear	7
Region	North Africa	Egypt (1)

	West Africa	Benin, Burkina Faso, Ghana, Mali, Nigeria, Sierra Leone (32)
	Central Africa	Cameroon, Gabon (5)
	Eastern Africa	Ethiopia, Kenya, Madagascar, Rwanda, Sudan, Tanzania, Uganda (85)
	Southern Africa	Botswana, Eswatini, Malawi, Mozambique, Namibia, South Africa, Zambia, Zimbabwe (45)
Type of facility*	Hospitals	95
	Primary Health care facilities	90
	Pharmacies/Dispensaries	45
	Community services	5
	Others (Clinics, Medical centres, National essential list committees)	4
	Unclear	13
Location of health facility*	Rural	25
	Peri-Urban	11
	Urban	26
	Rural and Urban	36
	Peri-urban and Urban	6
	Rural, Urban, Peri-Urban	4
	Unclear	74

*Some studies reported more than one detail

Study designs of included studies

Overall, most of the studies (n=129, 75%) in our review used quantitative study designs, followed by qualitative (n=26, 15%) and mixed methods (n=17, 10%). Studies with quantitative methods were mainly descriptive cross-sectional designs (n=104, 60%), followed by experimental or intervention studies (n=11, 6%) and cohort study designs (n=5, 3%). A summary of EDL study designs is presented in Table 1, and EML studies in Table 2.

All studies with a sole focus on EDL were cross-sectional study designs. Most studies on EML were quantitative studies (n=125, 73%) and mostly descriptive cross-sectional studies.

Themes about barriers and enablers

Barriers and enablers facing the EDL and EML were similar and were mostly about health system constraints. We present key themes about the barriers and enablers of the EML and EDL stratified in SURE themes below: At the individual level, themes about recipients of care, providers of care, and other stakeholders included their knowledge and skills, attitudes, and motivation to implement the WHO essential lists. Themes about health systems were myriad and will focus on the results section. Themes about social and political levels included ideologies, contracts, legislation or regulations, donor policies, influential people, corruption, and political stability.

Barriers and enablers for the implementation of the EDL and EML

A summary of themes about barriers facing the EDL and EML in the health system domain is presented in Fig 2. Themes about health systems constraints facing the EDL and EML were similar in included studies and mainly were about health system-level constraints. They included: limited availability of essential medicines and diagnostics at primary health care facilities compared to higher-level health facilities, lack of human resources, limited access to care facilities by patients due to financial and geographical constraints, procurement and distribution systems leading to regular stockouts, poorly resourced health facilities due to limited health facility operational funds, inefficient information systems and limited staff training. These barriers challenge implementing essential lists, especially the novel WHO EDL across countries. Other significant challenges unique to the EDL included lack of proper equipment and supplies, inadequate infrastructure, and space to facilitate laboratory and diagnostics services

and a shortage of skilled laboratory staff to support the implementation of the EDL at different health care levels as guided in the WHO EDL. The prominent themes about barriers to the implementation of the EDL and EML are presented in Table 3 and Table 4, respectively.

Table 3: Thematic analysis of the 9 applied SURE codes to barriers for the implementation of EDL

Proportion of total themes per code	
Health system constraints	
Facilities (N=9, n=17)	
Unavailability of tests	11 (65%)
Reagent stock-outs	3 (18%)
Lack of proper equipment	2 (12%)
Inadequate infrastructure and space	1 (6%)
Accessibility of care (N=6, n=8)	
Poor financial access	4 (50%)
Poor health facility access	2 (25%)
Poor geographical access	1 (12.5%)
Poorly resourced health facilities	1 (12.5%)
Procurement and distribution (N=3, n=3)	
Poor supply chain management including poor quantification and low inventory levels	3 (100%)
Human resources (N=3, n=3)	
Shortage of laboratory staff	1 (33%)
Inadequate number of qualified and skilled lab staff	1 (33%)
General shortage of health worker	1 (33%)
Information systems (N=3, n=3)	
Absence of clinical case registries	2 (67%)
Unavailability of operational data	1 (33%)
Financial resources (N=2, n=2)	
Inadequate health facility operational funds	1 (50%)
High test costs	1 (50%)
Education system (N=2, n=2)	
Improper training of laboratory staff	1 (50%)
Lack of training	1 (50%)
Relationship with norms and standards (N=1, n=1)	
Poor availability of guidelines	1 (100%)
Social and Political constraints	
Legislation or regulations (N=1, n=1)	
Insufficient policy	1 (100%)

N=number of studies that cited the SURE theme, n= frequency of applied codes per SURE theme
SURE= Supporting the Use of Research Evidence

Table 4: Thematic analysis of the most applied SURE codes to barriers for the implementation of EML

Proportion of total themes per code	
Health system constraints	
Facilities (N=76, n=81)	
Low availability of essential medicines in health facilities	45 (56%)
Unavailability of essential medicines in public and lower-level health facilities	15 (19%)
Inadequate health facility capacity	10 (12%)
Human resources (N=44, n=62)	
Lack of human resource	19 (31%)
Inadequate capacity of health workers	11 (18%)
Low number of specialized healthcare workers	8 (13%)
Accessibility of care (N=35, n=53)	
Poor financial access	22 (42%)
Poor geographical access	16 (30%)
Poor health facility access	15 (28%)
Procurement and distribution systems (N=40, n= 49)	
Inefficient procurement processes	16 (33%)
Poor stock management	10 (20%)
Inefficient distribution systems	9 (18%)
Relationship with norms and standards (N=33, n= 35)	
Unavailability of guidelines	16 (46%)
Incompliance to guidelines	8 (23%)
Incompliance to national EMLs	6 (17%)
Financial resources (N=25, n=25)	
Insufficient health facility funding	22 (88%)
Late claimant rebates from national insurance agencies	2 (8%)
Poor effect of financial autonomy	1 (4%)
Information systems (N=18, n=18)	
Poor information management practices	7 (39%)
Lack of reporting procedures and ordering systems	4 (22%)
Inadequate information systems	4 (22%)
Clinical supervision (N=11, n= 11)	
Lack of supportive supervision	9 (82%)
Inadequate health worker supervision	2 (18%)
Educational system (N=10, n=10)	
Lack of staff training	6 (60%)
Lack of specialized training	3 (30%)
Lack of educators to train health workforce	1 (10%)
Allocation of authority (N=10, n= 10)	
Limited facility manager authority on facility budget, procurement, pricing, and supply of medicines	7 (70%)
Lack of health workers involvement in drug selection and procurement	2 (20%)
Lack of autonomy by community members and facility managers on the community health fund	1 (10%)
Accountability (N=8, n=10)	
Lack of accountability of authorities on medicine orders, procurement, distribution, and stock management	10 (100%)
Management and or leadership (N=9, n=9)	
Inadequate leadership and coordination capacity	7 (78%)
Inadequate leadership support to rural-based health workers	1 (11%)
Lack of knowledge and skills by health workers working in managerial roles	1 (11%)
Internal communication (N=9, n=9)	
Lack of coordination among stakeholders, health managers, and health facilities	6 (67%)
Poor communication of policy change	2 (22%)
Limited communication between health facilities	1 (11%)

Incentives (N=6, n=6)	
Low motivation of health workers including high workload, poor remuneration, and non-payment of stipends	4 (67%)
Non-payment of suppliers	1 (16%)
Low tax incentives and subsidies to pharmaceuticals	1 (16%)
Bureaucracy (N=5, n=5)	
Bureaucratic decision making with limited evidence	5 (100%)
Patient flow processes (N=5, n=5)	
Poor referral practices	5 (100%)
External communication (N=2, n=2)	
Lack of information/communication material for provision of standard care	1 (50%)
Insufficient levels of essential information for consumers	1 (50%)
Social and Political constraints	
Legislation or regulations (N=34, n=36)	
Lack of pricing policy	10 (28%)
Incompliance to regulations	7 (19%)
Lack of structured guidelines	5 (14%)
Donor policies (N=6, n=6)	
Donors influence on the implementation of EML	4 (67%)
International procurement policies of donors	1 (17%)
Poor policy adoption from the global to national level	1 (17%)
Influential people (N=5, n=6)	
Pharmaceutical promotions to influence prescription practice and revisions of standard treatment guidelines	2 (33%)
International recommendations	1 (17%)
Lack of support to local pharmaceutical production	1 (17%)
Ideology (N=4, n=4)	
Market ideologies	1 (25%)
Political ideologies	1 (25%)
Community beliefs and attitudes	1 (25%)
Corruption (N=4, n=4)	
Corruption practices in public companies	3 (75%)
Trading of counterfeit medicines	1 (25%)
Contracts (N=3, n=3)	
Absence of national medical contracts	1 (33%)
Delay in contracting pharmaceutical tenders	1 (33%)
Absence of structure contracts	1 (33%)
Political stability (N=1, n=1)	
Political instability	1 (100%)
Individual level constraints	
Providers of care	
Knowledge and skills (N=21, n = 21)	
Inadequate training on current evidence-based treatment	8 (38%)
Insufficient number of skilled healthcare workers	5 (24%)
Inadequate providers knowledge on disease management	3 (14%)
Motivation to change or adopt new behaviour (N=8, n=10)	
Underpayment of healthcare workers	3 (30%)
High workload	2 (20%)
Limited supervision, career, and training opportunities	2 (20%)
Attitudes towards programme (N=6, n= 6)	
Quality concerns of medicines from some manufacturers	1(17%)
Negative attitude towards new quality improvement projects	1(17%)
Poor perceptions and awareness of child-appropriate medicine dosage formulations	1(17%)
Recipients of care	
Attitudes towards programme (N=9, n=10)	
Preference for private pharmacies to primary health care centres	2 (20%)
Social cultural influences	2 (20%)
Use of alternative treatments	2 (20%)
Motivation to change or adopt new behaviour (N=6, n=7)	

Unaffordability of medicines	2 (29%)
Low availability of drugs in health facilities	1 (14%)
Poor access to health facilities	1 (14%)
Knowledge and skills (N=2, n=2)	
Inadequate consumer knowledge on drugs	1 (50%)
Insufficient understanding of diseases	1 (50%)
Other stakeholders	
Knowledge and skills (N=5, n= 5)	
Inadequate training on rational use of medicines	2 (40%)
Inadequate knowledge on health commodities and financial report	1 (20%)
Unequal access to information on medical products	1 (20%)
Motivation to change or adopt new behaviour (N= 4, n=4)	
Inadequate drugs and medical supplies	2 (50%)
Low motivation to participate in healthcare programmes	1 (25%)
Poor health worker and patient relationships	1 (25%)

N=number of studies that cited the SURE theme, n= frequency of applied codes per SURE theme
SURE= Supporting the Use of Research Evidence

The themes about enablers for implementing both the EML and EDL are opposite to the health system barriers listed above. They are about tackling the listed barriers and have been summarised in Fig 3.

Individual-level

In this section, we present individual-related themes identified for the implementation of the EML.

Providers of care

Knowledge and skills

Barriers related to knowledge and skills were the most prominent theme under the providers of care domain. The main barriers identified included inadequate training on current evidence-based treatment ^{33–40}, an insufficient number of skilled healthcare workers ^{41–45}, and inadequate providers' knowledge of disease management ^{46–48}. Other barriers included lack of knowledge of inventory management ^{49,50}, lack of awareness of available guidelines ⁵¹, and poor understanding of partner programmes ^{52,53}.

The knowledge and skills-related enablers for the implementation of the EML are opposite to the main barriers listed above ^{54–59}.

Motivation to change

The main barriers to motivation to change included underpayment of healthcare workers ^{60–62}, high workload as a result of shortage of staff ^{63,64} and limited supervision, career and training opportunities ^{62,65}. Other motivation related barriers cited include low levels of motivation to work due to lack of essential medicines and equipment for use in facilities ³⁶, delay in the payment of claimant rebates to health staff ⁶¹, and limited scientific evidence-informed decision-making ⁶⁶.

The provision of financial incentives to staffs in the pay for performance (P4P) programmes was identified as an enabler for the implementation of the EML ⁶⁷.

Attitudes regarding programme acceptability, appropriateness, and credibility

The identified barriers related to the attitudes of providers of care towards implementation of EML included quality concerns of medicines from some manufacturers ⁶⁸, negative staff attitudes towards new quality improvement projects ³⁶, poor perceptions and awareness of child-appropriate medicine dosage formulations ⁴⁶, limited prescription of pain medication and stigmatization of palliative care ⁴⁵, consideration of traditional medicines on other illnesses ⁶⁹, and concerns on adopted ICT systems for inventory management ⁷⁰.

The enablers identified related to the providers of care attitudes towards the implementation of the EML included satisfaction with the coverage of the social health insurance scheme ⁶¹, positive attitude towards the provision of ICT support to improve their medical knowledge and skills ⁷¹, and satisfaction with the quality of medicines ⁷².

Recipient of care

Attitudes regarding programme acceptability, appropriateness, and credibility

Patients' attitudes regarding acceptability, appropriateness and credibility related to EML implementation were the most prominent theme under the recipient of care. The main barriers reported include preference to seek care from private pharmacies than primary health care centres due to lack of essential drugs and beliefs on the quality of medicines ^{68,73}, social-cultural influences ^{74,75}, and use of alternative treatments (traditional medicine) ^{68,73}. Other barriers reported include perception of the unaffordability of drugs ⁷⁶, uncertainty on availability of services ⁷⁷, drug safety concerns ⁶⁴, and low health-seeking behaviour ⁷⁶.

Motivation to change

The reported barriers related to motivation to change were unaffordability of medicines ^{78,79}, low availability of drugs in health facilities ⁷⁶, poor accessibility to the facility ⁷⁴, poor patient and health workers relations ⁴¹, lack of social and welfare support ⁷⁴, and inadequate supplies in health facilities ⁸⁰.

The motivation to change related enablers for the implementation of the EML are opposite to the barriers reported above ^{34,52,58,75,76,81–86}.

Knowledge and skills

The barriers to receiving care knowledge and skills related to the EML implementation were mainly inadequate consumer knowledge of medical and technical information on drugs they purchase and insufficient understanding of disease management ^{87,88}.

The recipients of care knowledge and skills-related enablers for the implementation of the EML included adequate on prescribed drugs ⁵⁹ and adequate knowledge on conditions ^{34,89}.

Other stakeholders (*community health committees, community leaders, programme managers, donors, policymakers, opinion leaders*)

Knowledge and skills

The barriers related to other stakeholders' knowledge and skills reported include inadequate training on rational use of medicines ^{90,91}, inadequate knowledge of health commodities and financial reports amongst health facility and governing committee members ⁹², unequal access to information on medical products to all stakeholders ⁸⁸, and variation in the knowledge of child-appropriate dosage formulations among stakeholders ⁴⁶.

Knowledge and skills on the quality, safety, and efficacy of medicines and pharmacoeconomic evaluations by stakeholders in selecting medicines for the EML were cited as an enabler for the implementation of the EML ⁹³.

Motivation to change

Barriers related to the motivation to change are mainly inadequate drugs and medical supplies, limiting the provision of quality care ^{75,94}, low motivation to participate in healthcare programmes ⁹⁵, and poor health worker and patient relationships leading to poor health-seeking behaviour ⁸².

On the other hand, the provision of incentives to stakeholders was identified as an enabler of implementing EML. These included the provision of business incentives to owners of accredited drug dispensing outlets (ADDOS) ⁵⁵ and financial incentives through payment for performance (P4P) to health facilities, district and regional managers ⁶⁷ to improve service delivery, availability of medicines and medical supplies in poor and rural areas.

Health systems-level

Facilities

The most reported barrier to implementing WHO essential lists (EDL&EML) was the facility-related constraints (Table 3 and Table 4). Unavailability of EDL tests ^{6,96–102}, and reagent stock-outs ^{6,100,103} were the most prominent themes within the facility-related barriers to EDL implementation. Other EDL barriers referenced lack of proper equipment and supplies described as low availability of key consumables for laboratory diagnosis, limited items of the major laboratory equipment's ^{6,96}, and inadequate infrastructure and space ⁹⁶ to facilitate laboratory and diagnostics services. Similarly, in the EML implementation, the most prominent themes within this barrier were low availability and unavailability of essential medicines ^{38,40,46,51,82,89,104–112}.

The enabler themes for the EDL implementation are opposite to the EDL barriers mentioned above ^{113,114,115, 103}. The EML enablers are opposite of the EML barriers reported above, and mainly included availability of essential medicines in facilities ^{34,37,48,57–59,66,87,92,108,116–137}, and adequate capacity of facilities to provide care ^{34,138}.

Accessibility of care

Accessibility of care-related barriers to EDL implementation was one of the most prominent barriers identified at the health system-level. The most prominent theme under this EDL barrier was poor financial access. This included limited access to care facilities by patients due to financial constraints: out of pocket expenses ^{103,139} and high test costs ^{96,99}. Other EDL barriers were poor geographical access contributing to limited access to essential in vitro diagnostics in rural areas ⁹⁶, and limited health facility access: availability of essential in vitro diagnostics at referral hospitals but not primary health care facilities ⁹⁶ and public facilities ⁹⁸, and poorly resourced health facilities ⁹⁷. The barriers for the implementation of the EML are similar to the EDL barriers reported above, and the main barriers were poor financial access ^{39,48,78,79,83,86–89,104,110,136,140–149}, poor geographical access ^{36,65,74,82,104,143,146,150} and health facility access ^{73,74,106,150–152}.

The accessibility of care related-enablers for the implementation of both the EDL ^{96,98,103} and EML ^{48,50,53,69,79,84,87, 68,69, 57,128,134, 85, 64, 83,104,133,} are opposite to the barriers listed above.

Human resources

The human resources-related barriers were a prominent barrier to implementing the WHO essential lists. Shortage of laboratory staff ⁹⁶, inadequate number of qualified and skilled laboratory staff ¹¹⁴, and a general shortage of health care workers ¹⁰⁰ were identified as the main barriers to implementing EDL. Similar human resources-related barriers to the EDL were reported in the implementation of the EML. Barriers unique to the EML included limited staff training ^{105,34,35,51,107,47,51,131,153}, high workload ^{63,75,111,123,143,154} and low number of specialized health care workers ^{106,116,125,154}. Other cited EML barriers included inequitable access to health care workers in rural areas ^{37,43,57}, inequitable training in lower-level facilities ¹¹⁹, and inadequate capacity of the essential medicines committee ⁶⁶.

Human resources-related enablers for the implementation of EML reported include sufficient capacity of health care workers ^{138,155}, adequate training provided to health care workers ^{58,156}, and availability of health care workers ⁵⁷.

Procurement and distribution systems

Poor supply chain management including poor quantification ^{6,102} and low inventory levels ¹⁰¹ leading to stock-out supplies in health facilities were identified as barriers to EDL implementation. Similar and other related barriers were also cited in the EML implementation. The main barriers unique to the EML included inefficient procurement processes ^{34,47,49,63,65,69,70,82,157}, poor stock management practices ^{39,49,50,53,94,105,107,140,158,159}, and inefficient distribution systems ^{40,49,75,94,111,131,146,160,161}. Other barriers highlighted included poor quantification of medicines and medical supplies at facility level ^{49,87,131,160,162}, and kits from national medical stores ^{115,163},

limited procurement funding for essential medicines ^{46,93}, lack of training of staffs in procurement ¹⁴⁶, distribution monopoly by national medical stores ⁷¹, inappropriate selection of medicines ¹³¹, and poor monitoring and evaluation ⁴⁹.

Adequate inventory management was identified as an enabler in the EDL implementation ¹⁰¹. The EML enablers were identified are the opposite of the EML barriers highlighted above ^{49,50,62,64,68,70,92,121,122,130,164}.

Relationship with norms and standards

The barriers related to the relationship with norms and standards for the EDL implementation included poor availability of diagnosis and management guidelines, noting the unavailability of diabetes guidelines in any surveyed clinics ¹⁶⁵. A similar barrier was identified in the implementation of the EML. Unavailability of guidelines was the most prominent theme within the barriers related to relationship with norms and standards for the EML implementation ^{35,66,86,106,110,116,154,166,143,59,106,119,131,143,155,167}. Other barriers unique to the EML included in compliance to guidelines ^{50,53,131,149,153,166,168,169}, in compliance to national EMLs ^{48,68,79,132,145,170}, lack of national EMLs in facilities ^{128,171}, disconnect between guidelines on treatment protocols ^{47,75}, disconnect between policy, guidelines and practice ^{46,167}, and lack of standard operating procedures ¹³⁵.

The enablers for the EDL and EML are opposite to the barriers mentioned above ^{113,33,63,68,79,92}. The enabler unique to the EML was compliance with the national EML in rural settings compared to urban ⁶⁸.

Financial resources

Inadequate health facility operational funds ⁹⁶ and high test costs due to much greater resource requirements depending on the type of diagnostics test ⁹⁹ were identified as barriers to EDL implementation. Similar financial constraints were also reported in implementing the more established EML. Inadequate funding was the most prominent theme within financial constraints barrier to the implementation of EML ^{95,34,46,172,131,159,173,174,43,137,153,154,158,94,109,110,146,149,163,175}.

The financial resources-related enablers for the implementation of the EML are opposite to the barriers reported above ^{120,121,123}.

Information systems

The information systems-related barriers to EDL implementation identified include the absence of clinical case registries ^{97,115} and the unavailability of operational data on EDL accessibility in some facilities ¹⁰¹. Similar barriers were identified in the implementation of EML ^{43,49,65,173}. Other barriers unique to the EML included poor information management practices ^{50,110,111,122,125,137,142} consisting of poor record-keeping, lack of standardized treatment protocols in health facilities, lack of reporting procedures and structured ordering systems ^{107,131,146,176}, and inadequate capacity to support information systems ^{70,105,138}.

The identified EML enablers were the opposite of the EML barriers. They mainly included good information practices ^{55,67,177,178}, access to record-keeping tools ³⁴, and utilization of information and communications technology (ICT) ^{68,129} to monitor real-time data on health facility drug consumption and stock levels.

Education system

The education system-related barriers to the essential list's implementation were related to the training of health workers. The EDL implementation barriers reported include improper staff training to provide laboratory tests ⁹⁶ and health workers' knowledge gaps, and lack of training ⁹⁷. Similar education system-related barriers are reported in EML studies ^{116,125,138,35,49,106,134,179,66,134}. Other barriers unique to the EML included lack of specialized training ^{116,125,138}, lack of training in the use of economic evidence essential in the selection of medicines ⁶⁶, and lack of educators to train the health workforce ¹³⁴.

Some studies identified education system-related enablers for the implementation of the EML. These included improved access to training ^{36,63,92} and in-service training to health workers ^{71,77}.

Clinical supervision

The main clinical supervision-related barriers to the EML implementation cited include lack of supportive supervision ^{51,63,68,73,77,111,153,156,159} and inadequate health worker supervision ^{65,130} to support the implementation of EML.

On the other, other EML studies cited regular supportive supervision as an enabler in implementing the EML ^{34,58,59,92}.

Allocation of authority

The allocation of authority-related barriers was only identified in EML and was related to decision making autonomy to support the implementation of EML. The main barrier identified includes limited authority by the facility managers on facility budget, procurement, pricing, and supply of medicines ^{70,87,95,110,160,179,180}. Other constraints included a lack of health workers' involvement in drug selection and procurement at facility level ^{50,149} and a lack of autonomy by the community members and facility managers on the community health fund ⁹⁴ to support health care programmes.

Allocation of authority was also reported as an enabler for EML implementation. Direct health financing to a facility led to a successful implementation of a prime vendor system (PVS) due to financial autonomy and flexibility in using funds ⁹².

Accountability

Lack of accountability was highlighted as a barrier to EML implementation. These included a lack of accountability of authorities on medicines orders, procurement, distribution, stock management, and delay in disbursement of health funds ^{94,109,110,142,156}. Poor accountability of personnel in the ministry of health and community-based health insurance financing ^{87,110,156,164} and inconsistent inventory records ¹¹¹ in the facility were also highlighted as barriers to EML implementation.

Some studies cited sufficiently structured systems ⁹² and an adequate tracking/management system ⁸⁴ were enablers of accountability in the health system and implementation of EML.

Management and leadership

Management or leadership in the health systems was reported as a barrier to EML implementation. Reported barriers include inadequate leadership and coordination capacity to coordinate the support and collaboration by partners and stakeholders ^{46,77,35,63,179,181,92}, inadequate leadership support to rural-based health workers ¹⁵³ and lack of knowledge and skills among health workers working in managerial roles ³⁶ to further the implementation of EML.

Strong leadership and commitment of the ministry of health ¹²¹ and facility leadership were identified as enablers for implementing EML ⁷².

Internal communication

Lack of coordination among stakeholders, health managers, and health facilities was identified as the primary internal communication-related barrier to implementing EML ^{65,70,71,77,146,181}. Other identified EML barriers included poor communication of policy change leading to inconsistencies between the procurement list and national essential lists ^{50,166} and limited communication between health facilities ⁴¹.

Internal communication-related enablers to the EML included sufficient coordination and communication between health facilities and national medicine stores, health managers, and health care workers ^{129,160}.

Incentives

The low motivation of health care workers was the main incentives-related barrier to the EML implementation. This was related to high workload, poor remuneration, and

non-payment of stipends^{36,41,75,158}. Other barriers reported include non-payment of suppliers⁷⁰ and low tax incentives and subsidies to pharmaceutical companies¹⁷⁰ to support EML implementation.

The EML enablers identified included providing financial incentives to health system actors (facilities, health managers, and health care workers) through incentivised programmes and interventions that positively affected the quality of health service. These programmes included pay for performance (P4P) and performance-based financing (PBF), innovative financing strategies that provide financial incentives to health service entities and healthcare providers to achieve increased coverage of quality health services. These programmes, P4P^{67,182} and PBF^{183,184,62}, contributed to improved accessibility of care, availability of essential medicines in health facilities, motivated health care workers and managers, improved health information systems, and greater financial autonomy for health facilities, and increased accountability within the health system.

Bureaucracy

Unsupportive bureaucracy was identified as a barrier to the EML implementation. Studies reported bureaucratic decision-making with little or no evidence regarding procurement and supply of essential medicines^{46,87,94,105,166}.

Patient flow processes

The patient flow processes-related barriers to the EML were related to inadequate referral systems and poor referral practices^{41,75,77,112,146}. These included patients'

referrals conducted without receiving pre-referral treatment and without referral letters affecting the provision of care and treatment ^{41,75,77,112,146}.

An adequate referral system was cited as an enabler to EML implementation ¹⁵².

External communication

Identified EML barriers were related to poor communication practices between health workers and recipients of care. These included lack of information/education/communication material for provision of standard care ¹⁴³ and insufficient levels of essential information for consumers when buying from drug shops ⁸⁸.

External communication was identified as an enabler for the implementation of EML are opposite to the EML barriers mentioned above ^{34,36,83,85,112,156,179,128}.

Social and Political-level

Legislation or regulations

The most frequently reported barrier at the social and political level was related to legislation or regulations (Table 3 and Table 4). Insufficient policy to facilitate access to essential diagnostics was identified as a barrier to the EDL implementation ⁹⁷. Barriers unique to the EML included lack of price regulations or pricing policy ^{78,86,89,108–110,141,148,174,180}, in compliance to regulations ^{38,46,88,133,145,176,185}, lack of structured guidelines for registration and control ^{72,73,116,126,186}. Other barriers included lack of policies ^{73,153,155}, inadequate policies that provide control and use of medicines ^{44,53,187},

long registration process ^{68,146,170}, restriction on the use of medicines ^{41,142}, lack of political will in implementing policies ¹⁵⁹, lack of a regulatory body for certifying and professionalizing medical, logistical companies ¹⁵⁹, and inadequate procedures ¹⁴⁹.

The EML enablers reported include supportive health financing policy reforms ^{142,188} and the presence of a structured registration process ⁶⁶ that supported the implementation of the EML.

Donor policies

Donor policies were also cited as barriers to the EML implementation. The donors' influence on EML implementation was reported as a primary barrier. This type of barrier referenced provision of donations irrespective of need, lack of donor priority and operation of donor-funded goods outside registration frameworks ^{50,128,146,164}. Other barriers referenced international procurement policies of donors and NGOs disadvantage local producers ¹⁷⁰, and poor policy adoption from the global to national level ⁴⁶ as barriers to EML implementation.

Donor's collaboration with government and faith-based organizations was highlighted as an enabler that improved the availability of essential malarial medicines in health facilities ¹³³.

Influential people

The influential people-related barriers to the EML implementation included pharmaceutical promotions to influence prescription practice and revisions of standard treatment guidelines ^{50,66} and implementation of international recommendations

separate from other national programmes, for instance, the vertical programmes ⁶⁶. Other barriers included the limited influence of health care managers on policy and resource development ³⁶, lack of support to the local pharmaceutical production leading to reliance on importations ⁶⁸, and donors' operation outside the policy framework ⁴⁶.

On the other hand, the influence of government agencies on the wholesale-to-retail market ⁸⁸ and international organizations described as WHO technical support to the government on the guidance and development of WHO model lists, and WHO classification of antimicrobial ¹⁷⁵ were identified as enablers to the implementation of the EML.

Ideology

Barriers to the EML implementation included market ideologies where generic medicines enter the market without a review process ¹⁴², and political ideologies where facilities are built for political and economic purposes and without the involvement of the communities ⁷³ and a disconnect between insurance drug list and drug prescription guidelines ⁴¹. Community beliefs and attitudes negatively influenced the use of internationally controlled essential medicines (ICEMs) by patients with end-stage diseases ¹⁴⁶.

Corruption

The main corruption-related barrier to the implementation of EML referenced was corruption practices in public companies. This is coupled with awarding tenders to companies without the capacity to supply medical supplies, providing financial

incentives to pharmacists from pharmaceutical to dispense specific drugs, and tenders^{68,70,72}. The trading of counterfeit medicines was also identified as a barrier to implementing EML¹²⁴.

Contract

The contract-related barriers were only identified in EML. The barriers identified include the absence of national medical contracts in regional code list¹⁶⁰, delay in contracting pharmaceutical tenders¹⁶⁰, and absence of structured contracts leading to awarding tenders to companies without the capacity to deliver⁷⁰.

Political stability

Political unrest was identified as a barrier to the implementation of the EML. It impacted health care workers staffing in the affected areas³⁶.

Quality of evidence

One hundred and sixty-seven (97%) articles were appraised for quality. In this scoping review, 56 (33%) articles were graded as having high quality, 52 (30%) articles were graded as having considerable quality, 54 (31%) articles studies were graded as having moderate quality, and 5 (3%) articles were graded as having poor quality (Table 5). Five articles did not provide sufficient information to permit a complete MMAT appraisal and were graded as unclassified. See S3 Appendix for detail of the quality assessment for each study.

Table 5: Distribution of MMAT scores (0 = lowest score and 100 = highest score)

MMAT Score distribution	Number of studies (%)
20	5 (3)
40	17 (10)
60	37 (21)
80	52 (30)
100	56 (33)
Total	172 (100)

Discussion

This scoping review was conducted to map evidence on implementing the WHO's essential lists in Africa to guide the effective implementation of the new WHO EDL. Our comprehensive scoping review identified themes based on the SURE framework into the barriers and enablers for implementing WHO essential lists across 172 articles. In lieu of the novelty of the EDL, there was limited published primary research on the implementation of WHO EDL. We found many studies reporting evidence on the implementation of EML in Africa. The review findings showed that the main theme barrier facing the more established EML, and newly introduced EDL was poorly equipped health facilities that entailed unavailability of essential in vitro diagnostics and medicines, stock-outs of laboratory reagents, and inadequate infrastructure and space to enable health service delivery. The EDL implementers at the national levels can work on equipping health facilities to improve the impact of the EDL.

Most of the studies in our review used quantitative methods, with nearly two-thirds of all studies using cross-sectional study designs in the surveys. There were fewer qualitative studies, mixed-methods studies, and randomized trials. Qualitative studies are useful for exploring and understanding barriers and facilitators for the EDL at context levels ¹⁸⁹. Experimental trials are more useful for testing interventions that may improve the effectiveness of the EDL on health outcomes ¹⁹⁰.

Similar work to ours, a systematic review by Peacocke et al., ¹⁹¹ explored the process of adapting the WHO EML at the national level. The authors provided key insights on the complexities and interdependencies essential to the implementation of the EML. Their review focused on key factors influencing the adaptation and implementation

process of the EML at the macro level of the health system: country-level institutional structure; legislative and regulatory frameworks; governance, leadership and coordination for NEMs. Our review provides further insights and maps evidence on implementing the WHO EDL and EML at national levels, focusing on the African context. In this review, we present barriers and enablers facing the EDL and EML at different levels of implementation; individual, health system, and social and political levels that influence the implementation of the WHO essential lists in-depth.

The essential lists and, more recently, the EDL by themselves are not sufficient to ensure their impact on access and health outcomes. A good health system is vital to strengthen the existence of the lists. Indeed, our review highlighted that health systems constraints remain the main barrier to implementing the EDL and EML. Such barriers included poorly equipped health facilities which entailed limited availability of essential tests and medicines, limited access to care facilities by patients due to financial and geographical constraints, availability of essential medicines and diagnostics at referral hospitals but not primary health care facilities, limited staff training, inefficient information systems, and inefficient procurement processes leading to regular stock-outs. In Africa, health systems face complex challenges such as the continued burden of communicable and non-communicable diseases pandemics amidst limited resources^{192–194}. In addition, many influencing factors in the health system determine the access, implementation, and effectiveness of diagnostic tests. Dealing with such challenges requires that decisions on health systems are informed by robust evidence that applies to the local context. Policymakers and health decision-makers can look to evidence-informed approaches, especially the synthesis of health policy and systems evidence, and contextualize findings to their settings. Methods for conducting or

utilizing health systems synthesis can be found in the WHO methods guide for evidence synthesis for health policy and systems ¹⁹⁵.

Evidence-informed approaches are useful in guiding the adapting process and improving the implementation of the lists. WHO has a guidance resource for enabling African countries to adopt the WHO EDL to national contexts ¹⁹⁶. To our knowledge, in Africa, Nigeria is the only country that has adapted the WHO EDL list and developed its own national EDL ¹⁹⁷. Many African countries have adopted the WHO EML in national settings. However, stock-outs and limited access to medicines persist, emphasising the importance of enabling health systems to strengthen the implementation of the essential lists and ensure their impact. Evidence about the evidence-informed approaches or processes in adapting the EML has been published by South Africa ⁹³, Ghana ¹⁷⁵, and Tanzania ⁶⁶. These publications highlighted enablers such as a well-structured and rigorous process ^{93,175}, utilization of evidence summaries in decision making ^{93,175}, involvement of a diverse committee and stakeholder engagements ^{93,175}. Challenges included insufficient and intermittent funding ¹⁷⁵, limited use of scientific evidence ⁶⁶, lack of expertise in evidence synthesis ^{66,175} and health economic analyses ^{66,93} in the review and development of NEML. Besides providing adaption guides for the essential lists, the implementation handbook guides can be released in conjunction with the versions of the model lists.

The WHO also released a handbook for monitoring the building blocks of health systems structured around the six main building blocks of WHO health systems framework's: service delivery, health workforce, health information systems, access to essential medicines, financing, and leadership and governance ¹⁹⁸. The proposed measures of health systems performance are crucial in health systems strengthening

and valuable tools to accurately monitor the health system's progress across the six building blocks over time. It facilitates the development of a sound Country monitoring strategy providing an enabling environment and sustainable scale-up of governance tools such as the EML and the newly introduced EDL. The EML and EDL play a vital role in realising UHC and access to quality health service delivery ¹⁹⁹. The impact of the essential medicine and diagnostics lists will become truly effective only in well-functioning strengthened health systems. The core indicators to performance measures of key building blocks, including access to essential medicines and technologies, health service delivery, health workforce, health information systems, health financing, and leadership and governance ¹⁹⁸, are all critical to the development, review, and implementation of the essential lists. The use of core indicators in the health systems could also assist in addressing EDL and EML implementation barriers timely, efficiently, and effectively to impact populations' health outcomes.

In this review, there were notable successes of interventions developed to address barriers to the EML implementation that could be considered useful in the EDL implementation. The RDF ^{92,121,200}, PBF ^{183,184,119}, and P4P ^{67,182} interventions addressed several barriers to implementing the EML: accessibility for care-related barriers, facility-related barriers, incentive-related barriers, information system-related barriers, accountability-related barriers, and facility financial resource-related barriers. The revolving fund pharmacy (RFP) ²⁰¹, accredited drug dispensing outlets (ADDOS) ⁵⁵, and auditable pharmaceutical services and transaction system (APTS) ⁸⁴ interventions also addressed the facility-related barriers. They contributed to the improved availability of essential medicines. Procurement and distribution-related barriers were addressed through direct distribution of supplies from partners ^{50,60,130,164,167}, PBF ⁶², RDF programmes ^{92,121,200}, and utilization of ICT ^{68,70} in stock

management. Similar interventions could be used to address the shortfalls of the EML and strengthen the EDL implementation designs. However, considering the country's context and specificities to be addressed will be crucial when implementing interventions. Some interventions worked in some contexts and did not work in other contexts. For instance, the effect of PBF intervention did not affect the stock-out rate of essential medicines compared to payments not tied to the performance of essential medicines in some contexts ¹⁶⁴. On the other hand, the provision of financial incentives in the P4P intervention addressed some of the health systems barriers; still, it was reported to have no evidence for increasing healthcare workers' motivation ¹⁸². Though financial and non-financial incentives may motivate implementation, they can unrealistically raise expectations and hinder implementation in the long run due to sustainability issues ²⁰².

We evaluated the existing literature through a systematic and rigorous process that involved reviewing qualitative, quantitative, and mixed methods studies using established guidance for scoping reviews. To inform the implementation of EDL, we also referred to a representative sample of the established EML. We did not include non-English studies hence could have missed studies published by French, Portuguese, or Arabic-speaking African countries. Secondly, due to accessibility limitations, we excluded 52 EML articles and multi-country studies about EML (n=67) due to the vast number of full-text EML studies and high likelihood of data saturation given rich, in-depth information from single countries in the multiple numbers of available studies. We also did not explore the process of adapting the WHO essential list to national contexts. Trend analysis from EML inception to the date of implementation aspects of the EML would help identify the successes, pitfalls, and

plateaus of EML implementation over four decades. However, this was out of the scope of this work.

There has been limited primary research published on essential in vitro diagnostics in Africa since the introduction of the WHO EDL in 2018. Further studies can be conducted to provide contextual insights on the capacity of health systems to support the successful implementation of national EDLs bearing in mind the need to improve access to essential in vitro diagnostics in Africa. Consideration of dissemination and implementation frameworks such as the CFIR (Consolidated Framework for Implementation Research) ^{203,204}, RE-AIM (Reach, effectiveness, adoption, implementation, and maintenance) ^{204,205}, and PRISM (practical, robust implementation sustainability model) ^{206,207} frameworks would be crucial when planning the implementation of the essential lists to guide adoption, adaptation, and evaluation of the lists. Qualitative research and process evaluations can be done to evaluate the impact of the essential lists and identify enablers and challenges to their implementation. More implementation trials or experimental studies can be conducted to assess effective interventions in different settings.

Conclusion

The most dominant constraints facing EML implementation, a more established WHO essential list and the new EDL are mainly about the health system. The main theme barrier was poorly equipped health facilities, including limited availability of essential in vitro diagnostics and medicines and stock-outs, which mainly limit the implementation of the EML and EDL as well. The EDL implementation can learn from interventions to improve the availability and supply of essential medicines. When developing and implementing the National EDLs, consideration of these barriers will strengthen health

service delivery, access to essential diagnostics and universal health coverage. Financial and non-financial incentives may be enablers, but their effect varies in different contexts.

Acknowledgements

We thank Vittoria Lutje, Information Specialist at the Liverpool School of Tropical Medicine, who advised on and developed the search strategy. The authors express their gratitude to the Kenya Medical Research Institute for the support provided for this review.

Contributors

MN, EO, and MM conceptualized and designed the study. MN, MM, BN, EJO, and EO contributed to the abstract and full article screening, data extraction, quality assessment, and synthesis of the included studies. MN prepared the first draft, and all authors critically reviewed the draft. EO is the senior researcher on the team, providing overall guidance.

Funding

This study was funded by UK National Institute for Health Research (NIHR) Global HPSR developmental award (130222). NIHR has no role in the design, conduct, and interpretation of this review.

Competing interests

None declared

References

1. World Health Organisation (WHO). Universal health coverage (UHC) [Internet]. 2019 [cited 2021 Mar 25]. Available from: [https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-\(uhc\)](https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc))
2. Schroeder LF, Pai M. A List To Cement the Rightful Place of Diagnostics in Health Care. McAdam AJ, editor. J Clin Microbiol [Internet]. 2018 Oct 1;56(10):e01137-18. Available from: <https://journals.asm.org/doi/10.1128/JCM.01137-18>
3. Fleming KA, Horton S, Wilson ML, Atun R, DeStigter K, Flanigan J, et al. The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet [Internet]. 2021; Available from: [http://dx.doi.org/10.1016/S0140-6736\(21\)00673-5](http://dx.doi.org/10.1016/S0140-6736(21)00673-5)
4. Wilson ML, Atun R, DeStigter K, Flanigan J, Fleming KA, Horton S, et al. The Lancet Commission on diagnostics: advancing equitable access to diagnostics. Lancet [Internet]. 2019 May 18;393(10185):2018–20. Available from: [https://doi.org/10.1016/S0140-6736\(19\)31052-9](https://doi.org/10.1016/S0140-6736(19)31052-9)
5. Velazquez Berumen A, Garner S, Hill SR, Swaminathan S. Making diagnostic tests as essential as medicines. BMJ Glob Heal [Internet]. 2018 Aug 1;3(4):e001033. Available from: <http://gh.bmj.com/content/3/4/e001033.abstract>
6. Shumbej T, Menu S, Gebru T, Girum T, Bekele F, Solomon A, et al. Essential in-vitro laboratory diagnostic services provision in accordance with the WHO standards in Guragae zone primary health care unit level, South Ethiopia. Trop Dis Travel Med vaccines [Internet]. 2020 Mar 6;6(4):1–7. Available from:

<https://pubmed.ncbi.nlm.nih.gov/32161656>

7. Sayed S, Cherniak W, Lawler M, Tan SY, El Sadr W, Wolf N, et al. Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions. *Lancet* [Internet]. 2018;391(10133):1939–52. Available from: [http://dx.doi.org/10.1016/S0140-6736\(18\)30459-8](http://dx.doi.org/10.1016/S0140-6736(18)30459-8)
8. Wilson ML, Fleming KA, Kuti MA, Looi LM, Lago N, Ru K. Access to pathology and laboratory medicine services: a crucial gap. *Lancet* [Internet]. 2018;391(10133):1927–38. Available from: [http://dx.doi.org/10.1016/S0140-6736\(18\)30458-6](http://dx.doi.org/10.1016/S0140-6736(18)30458-6)
9. Bhatia R. WHO essential diagnostics list (2018): A revolutionary step in strengthening health laboratories at all levels of healthcare. *Indian J Med Microbiol* [Internet]. 2018;36(2):153–4. Available from: <https://www.ijmm.org/text.asp?2018/36/2/153/238693>
10. Moussy FG, Berumen AV, Pai M. The WHO list of essential in vitro diagnostics: Development and next steps. *EBioMedicine* [Internet]. 2018/10/30. 2018 Nov;37:1–2. Available from: <https://pubmed.ncbi.nlm.nih.gov/30389503>
11. Vijay S, Gangakhedkar RR, Shekhar C, Walia K. Introducing a national essential diagnostics list in India. *Bull World Health Organ* [Internet]. 2021;99:236–8. Available from: <https://dx.doi.org/10.2471/BLT.20.268037>
12. African Society for Laboratory Medicine. ASLM2020 : Strategies and Vision to Strengthen Public Health Laboratory Medicine in Africa [Internet]. 2020 [cited 2021 Mar 25]. p. 2020. Available from: https://na.eventscloud.com/file_uploads/e46acabb2952cbecd2d610ca4cbfd45c

_ASLM2020.pdf

13. Nichols K, Girdwood SJ, Inglis A, Ondoa P, Sy KTL, Benade M, et al. Bringing Data Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income Countries: Process, Terms and Definitions. *Diagnostics* (Basel, Switzerland) [Internet]. 2020 Dec 24;11(1):22. Available from: <https://pubmed.ncbi.nlm.nih.gov/33374315>
14. World Health Organization. First WHO model list of essential in vitro diagnostics. [Internet]. 2019. Available from: <https://apps.who.int/iris/handle/10665/311567>
15. Pai M, Walia K, Boehme CC. Essential medicines and essential diagnostics: a package deal. *Lancet Public Heal* [Internet]. 2019 Oct 1;4(10):e492. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2468266719301653>
16. Sen P, Kohli M, Pai M. Industry Perspectives on the WHO Essential Diagnostics List. McAdam AJ, editor. *J Clin Microbiol* [Internet]. 2019 Feb 1;57(2):e01637-18. Available from: <https://journals.asm.org/doi/10.1128/JCM.01637-18>
17. Pai M, Kohli M. Essential Diagnostics: A Key Element of Universal Health Coverage. *Dr Sulaiman Al Habib Med J*. 2019;1(00):3–7.
18. World Health Organisation. Second WHO model of essential in vitro diagnostics [Internet]. Geneva; 2019. Available from: <https://apps.who.int/iris/handle/10665/331769>
19. World Health Organization. The selection and use of essential in vitro diagnostics: report of the third meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2020 (including the third WHO model list of essential in vitro diagnostics). [Internet]. World Health Organization technical

- report series. Geneva; 2021. Available from:
<https://apps.who.int/iris/handle/10665/339064>
20. Essential WEC on the S of D and WHO. The selection of essential drugs : report of a WHO expert committee [meeting held in Geneva from 17 to 21 October 1977] [Internet]. Geneva: World Health Organization; 1977. (World Health Organization technical report series; no. 615). Available from:
<https://apps.who.int/iris/handle/10665/41272>
21. World Health Organization. World Health Organization Model List of Essential Medicines – 22nd List, 2021. [Internet]. 2021. Available from:
<https://apps.who.int/iris/handle/10665/345533>
22. Atif M, Malik I, Dawoud D, Gilani A, Ahmed N, Babar Z-U-D. Essential Medicine List, Policies, and the World Health Organization. In: Babar Z-U-DBT-E of PP and CP, editor. Oxford: Elsevier; 2019. p. 239–49. Available from:
<https://www.sciencedirect.com/science/article/pii/B9780128127353003447>
23. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ [Internet]. 2011/03/14. 2011 Jun 1;89(6):412–21. Available from:
<https://pubmed.ncbi.nlm.nih.gov/21673857>
24. Wirtz VJ, Hogerzeil H V, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet (London, England) [Internet]. 2016/11/08. 2017 Jan 28;389(10067):403–76. Available from:
<https://pubmed.ncbi.nlm.nih.gov/27832874>

25. Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy Plan [Internet]. 2013 Oct 1;28(7):692–704. Available from: <https://doi.org/10.1093/heapol/czs108>
26. Nyanchoka M, Mulaku M, Kariuki S, Kuile F, Young T, Garner P, et al. Implementation considerations for the WHO Essential Diagnostics List with insights from the Essential Medicines List : A scoping review protocol. OSF Prepr [Internet]. 2021;1–10. Available from: <https://osf.io/cxwmu>
27. Peters M, Godfrey C, McInerney P, Soares CB, Khalil H, Parker D. The Joanna Briggs Institute reviewers' manual 2015: methodology for JBI scoping reviews. In 2015.
28. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med [Internet]. 2018 Sep 4;169(7):467–73. Available from: <https://doi.org/10.7326/M18-0850>
29. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc [Internet]. 2015 Sep;13(3):141–6. Available from: <https://journals.lww.com/01787381-201509000-00005>
30. Veritas Health Innovation. Covidence systematic review software [Internet]. Melbourne, Australia; Available from: www.covidence.org
31. The SURE Collaboration. SURE Guides for Preparing and Using Evidence-Based Policy Briefs. Version 2.1 [updated November 2011]. [Internet]. 2011. Available from: <http://www.evipnet.org/sure>.

32. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. *Educ Inf*. 2018;34:285–91.
33. Ayenew A, Abebe M, Ewnetu M. Essential Newborn Care and Associated Factors Among Obstetrical Care Providers in Awi Zone Health Facilities, Northwest Ethiopia: An Institutional-Based Cross-Sectional Study. *Pediatr Heal Med Ther* [Internet]. 2020 Nov;Volume 11:449–58. Available from: <https://www.dovepress.com/essential-newborn-care-and-associated-factors-among-obstetrical-care-p-peer-reviewed-article-PHMT>
34. Gebremedhin T, Daka DW, Alemayehu YK, Yitbarek K, Debie A. Process evaluation of the community-based newborn care program implementation in Geze Gofa district, south Ethiopia: a case study evaluation design. *BMC Pregnancy Childbirth* [Internet]. 2019 Dec 11;19(1):492. Available from: <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-019-2616-9>
35. Andriantsimietry S, Rakotomanga R, Rakotovao JP, Ramiandrison E, Razakariasy ME, Favero R, et al. Service Availability and Readiness Assessment of Maternal, Newborn and Child Health Services at Public Health Facilities in Madagascar. *Afr J Reprod Health* [Internet]. 2016 Sep 29;20(3):149–58. Available from: <https://ajrh.info/index.php/ajrh/article/view/217>
36. Kakyo TA, Xiao LD. Challenges faced in rural hospitals: the experiences of nurse managers in Uganda. *Int Nurs Rev* [Internet]. 2019 Mar;66(1):70–7. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/inr.12459>
37. Rutebemberwa E, Buregyeya E, Lal S, Clarke SE, Hansen KS, Magnussen P,

- et al. Assessing the potential of rural and urban private facilities in implementing child health interventions in Mukono district, central Uganda-a cross sectional study. BMC Health Serv Res [Internet]. 2016;16(268):1–7. Available from: <http://dx.doi.org/10.1186/s12913-016-1529-9>
38. Treleaven E, Liu J, Prach LM, Isiguzo C. Management of paediatric illnesses by patent and proprietary medicine vendors in Nigeria. Malar J [Internet]. 2015;14(232):1–9. Available from: <http://dx.doi.org/10.1186/s12936-015-0747-7>
39. Hailu AD, Mohammed SA. Availability, price, and affordability of WHO priority maternal and child health medicine in public health facilities of Dessie, north-East Ethiopia. BMC Med Inform Decis Mak [Internet]. 2020 Dec 11;20(1):221. Available from: <https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-020-01247-2>
40. Daniel G, Tegegnetwork H, Demissie T, Reithinger R. Pilot assessment of supply chains for pharmaceuticals and medical commodities for malaria, tuberculosis and HIV infection in Ethiopia. Trans R Soc Trop Med Hyg [Internet]. 2012;106(2012):60–2. Available from: <http://dx.doi.org/10.1016/j.trstmh.2011.09.008>
41. Sumankuuro J, Crockett J, Wang S. Perceived barriers to maternal and newborn health services delivery: a qualitative study of health workers and community members in low and middle-income settings. BMJ Open [Internet]. 2018 Nov 8;8(11):e021223. Available from: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2017-021223>
42. Maswime T, Buchmann E. Inequities in resources and preparedness for surgical

complications of caesarean section in southern gauteng hospitals. S Afr J Obstet Gynaecol. 2016;22(1):21–4.

43. Sambo LG, Kirigia JM, Ki-Zerbo G. Perceptions and viewpoints on proceedings of the Fifteenth Assembly of Heads of State and Government of the African Union Debate on Maternal, Newborn and Child Health and Development, 25–27 July 2010, Kampala, Uganda. BMC Proc [Internet]. 2011 Dec 13;5(S5):S1. Available from: <https://bmcproc.biomedcentral.com/articles/10.1186/1753-6561-5-S5-S1>
44. Amadi C, Tsui EK. How the quality of essential medicines is perceived and maintained through the pharmaceutical supply chain: A perspective from stakeholders in Nigeria. Res Soc Adm Pharm [Internet]. 2019;15(11):1344–57. Available from: <https://doi.org/10.1016/j.sapharm.2018.11.011>
45. Dekker AM, Amon JJ, le Roux KW, Gaunt CB. “What is Killing Me Most”: Chronic Pain and the Need for Palliative Care in the Eastern Cape, South Africa. J Pain Palliat Care Pharmacother [Internet]. 2012 Dec 5;26(4):334–40. Available from: <https://doi.org/10.3109/15360288.2012.734897>
46. Nsabagasani X, Hansen E, Mbonye A, Ssengooba F, Muyinda H, Mugisha J, et al. Explaining the slow transition of child-appropriate dosage formulations from the global to national level in the context of Uganda: A qualitative study. J Pharm Policy Pract [Internet]. 2015;8(19):1–10. Available from: <http://dx.doi.org/10.1186/s40545-015-0039-1>
47. Kiplagat A, Musto R, Mwizamholya D, Morona D. Factors influencing the implementation of integrated management of childhood illness (IMCI) by healthcare workers at public health centers & dispensaries in Mwanza,

- Tanzania. BMC Public Health [Internet]. 2014 Dec 25;14(1):277. Available from: <http://bmcpublikealth.biomedcentral.com/articles/10.1186/1471-2458-14-277>
48. Ozoh OB, Eze JN, Garba BI, Ojo OO, Okorie E, Yiltok E, et al. Nationwide survey of the availability and affordability of asthma and COPD medicines in Nigeria. Trop Med Int Heal [Internet]. 2021 Jan 14;26(1):54–65. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/tmi.13497>
49. Chukwu OA, Ezeanochikwa VN, Eya BE. Supply chain management of health commodities for reducing global disease burden. Res Soc Adm Pharm [Internet]. 2016;1–4. Available from: <http://dx.doi.org/10.1016/j.sapharm.2016.08.008>
50. Nakyanzi JK, Kitutu FE, Oria H, Kamba PF. Expiry of medicines in supply outlets in Uganda. Bull World Health Organ [Internet]. 2010 Feb 1;88(2):154–8. Available from: <http://www.who.int/bulletin/volumes/88/2/08-057471.pdf>
51. Seid SS, Sendo EG. A survey on Integrated Management of Neonatal and Childhood Illness implementation by nurses in four districts of West Arsi zone of Ethiopia. Pediatr Heal Med Ther [Internet]. 2018 Jan;Volume 9:1–7. Available from: <https://www.dovepress.com/a-survey-on-integrated-management-of-neonatal-and-childhood-illness-im-peer-reviewed-article-PHMT>
52. Rockers PC, Laing RO, Ashigbie PG, Onyango MA, Mukiira CK, Wirtz VJ. Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial. Lancet Glob Heal [Internet]. 2019;7(4):e492–502. Available from: [http://dx.doi.org/10.1016/S2214-109X\(18\)30563-1](http://dx.doi.org/10.1016/S2214-109X(18)30563-1)
53. Yevutsey SK, Buabeng KO, Aikins M, Anto BP, Biritwum RB, Frimodt-Møller N,

- et al. Situational analysis of antibiotic use and resistance in Ghana: policy and regulation. BMC Public Health [Internet]. 2017 Dec 23;17(1):896. Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4910-7>
54. Richard OT, Maghanga M, Kenneth O. Challenges Facing the Push and Pull Hybrid System in the Supply of Essential Medicines in Gulu, Northern Uganda. Am J Public Heal Res [Internet]. 2015;3(3):106–12. Available from: <http://pubs.sciepub.com/ajphr/3/3/5/index.html>
 55. Rutta E, Liana J, Embrey M, Johnson K, Kimatta S, Valimba R, et al. Accrediting retail drug shops to strengthen Tanzania’s public health system: An ADDO case study. J Pharm Policy Pract [Internet]. 2015;8(23):1–15. Available from: <http://dx.doi.org/10.1186/s40545-015-0044-4>
 56. Vledder M, Friedman J, Sjöblom M, Brown T, Yadav P. Improving Supply Chain for Essential Drugs in Low-Income Countries: Results from a Large Scale Randomized Experiment in Zambia. Heal Syst Reform [Internet]. 2019;5(2):158–77. Available from: <https://doi.org/10.1080/23288604.2019.1596050>
 57. Millogo O, Doamba JEO, Sié A, Utzinger J, Vounatsou P. Constructing a malaria-related health service readiness index and assessing its association with child malaria mortality: an analysis of the Burkina Faso 2014 SARA data. BMC Public Health [Internet]. 2021 Dec 5;21(1):20. Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09994-7>
 58. Mukose AD, Bastiaens H, Buregyeya E, Naigino R, Makumbi F, Musinguzi J, et al. Health Provider Perspectives of Health Facility Preparedness and

- Organization in Implementation of Option B+ among Pregnant and Lactating Women in Central Uganda: A Qualitative Study. *J Int Assoc Provid AIDS Care* [Internet]. 2019 Jan 1;18:232595821983393. Available from: <http://journals.sagepub.com/doi/10.1177/2325958219833930>
59. Namuyinga RJ, Mwandama D, Moyo D, Gumbo A, Troell P, Kobayashi M, et al. Health worker adherence to malaria treatment guidelines at outpatient health facilities in southern Malawi following implementation of universal access to diagnostic testing. *Malar J* [Internet]. 2017 Dec 23;16(1):40. Available from: <http://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1693-3>
 60. Tsofa B, Goodman C, Gilson L, Molyneux S. Devolution and its effects on health workforce and commodities management – early implementation experiences in Kilifi County, Kenya. *Int J Equity Health* [Internet]. 2017 Dec 15;16(1):169. Available from: <http://equityhealthj.biomedcentral.com/articles/10.1186/s12939-017-0663-2>
 61. Sanogo NA, Fantaye AW, Yaya S. Beyond coverage: a qualitative study exploring the perceived impact of Gabon's health insurance plan on access to and quality of prenatal care. *BMC Health Serv Res* [Internet]. 2020 Dec 30;20(483):1–16. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-020-05310-6>
 62. Brenner S, Wilhelm D, Lohmann J, Kambala C, Chinkhumba J, Muula AS, et al. Implementation research to improve quality of maternal and newborn health care, Malawi. *Bull World Health Organ* [Internet]. 2017 Jul 1;95(7):491–502. Available from: <http://www.who.int/entity/bulletin/volumes/95/7/16-178202.pdf>

63. Visser CA, Wolvaardt JE, Cameron D, Marincowitz GJO. Clinical mentoring to improve quality of care provided at three NIM-ART facilities: A mixed methods study. *African J Prim Heal Care Fam Med* [Internet]. 2018 Jun 14;10(1):1–7. Available from: <https://phcfm.org/index.php/phcfm/article/view/1579>

64. Mubyazi GM, Magnussen P, Byskov J, Bloch P. Feasibility and coverage of implementing intermittent preventive treatment of malaria in pregnant women contacting private or public clinics in Tanzania: experience-based viewpoints of health managers in Mkuranga and Mufindi districts. *BMC Health Serv Res* [Internet]. 2013 Dec 1;13(1):372. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-372>

65. Callaghan-Koru JA, Gilroy K, Hyder AA, George A, Nsona H, Mtimuni A, et al. Health systems supports for community case management of childhood illness: lessons from an assessment of early implementation in Malawi. *BMC Health Serv Res* [Internet]. 2013 Dec 11;13(1):55. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-55>

66. Mori AT, Kaale EA, Ngalesoni F, Norheim OF, Robberstad B. The Role of Evidence in the Decision-Making Process of Selecting Essential Medicines in Developing Countries: The Case of Tanzania. Tu Y-K, editor. *PLoS One* [Internet]. 2014 Jan 8;9(1):e84824. Available from: <https://dx.plos.org/10.1371/journal.pone.0084824>

67. Binyaruka P, Borghi J. Improving quality of care through payment for performance: examining effects on the availability and stock-out of essential medical commodities in Tanzania. *Trop Med Int Heal* [Internet]. 2017

- Jan;22(1):92–102. Available from:
<https://onlinelibrary.wiley.com/doi/10.1111/tmi.12809>
68. Rizk HI, Elkholy MM, Barakat AA, Elsayed RMM, Abd El Fatah SAM. Perspectives of pharmaceutical stakeholders on determinants of medicines accessibility at the primary care level. J Egypt Public Health Assoc [Internet]. 2021 Dec 13;96(1):1. Available from:
<https://jepha.springeropen.com/articles/10.1186/s42506-020-00062-x>
69. Kayombo EJ, Uiso FC, Mahunnah RLA. Experience on healthcare utilization in seven administrative regions of Tanzania. J Ethnobiol Ethnomed [Internet]. 2012 Dec 27;8(1):5. Available from:
<https://ethnobiomed.biomedcentral.com/articles/10.1186/1746-4269-8-5>
70. Modisakeng C, Matlala M, Godman B, Meyer JC. Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications. BMC Health Serv Res [Internet]. 2020 Dec 19;20(1):234. Available from:
<https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-020-05080-1>
71. Nilseng J, Gustafsson LL, Nungu A, Bastholm-Rahmner P, Mazali D, Pehrson B, et al. A cross-sectional pilot study assessing needs and attitudes to implementation of Information and Communication Technology for rational use of medicines among healthcare staff in rural Tanzania. BMC Med Inform Decis Mak [Internet]. 2014 Dec 27;14(1):78. Available from:
<https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/1472-6947-14-78>

72. Patel A, Gauld R, Norris P, Rades T. Quality of generic medicines in South Africa: Perceptions versus Reality – A qualitative study. BMC Health Serv Res [Internet]. 2012 Dec 3;12(1):297. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-12-297>

73. Muhammed KA, Umeh KN, Nasir SM, Suleiman IH. Understanding the barriers to the utilization of primary health care in a low-income setting: implications for health policy and planning. J Public Health Africa [Internet]. 2013 Oct 7;4(2):13. Available from: <http://publichealthinafrica.org/index.php/jphia/article/view/jphia.2013.e13>

74. Mugo NS, Dibley MJ, Damundu EY, Alam A. “The system here isn’t on patients’ side”- perspectives of women and men on the barriers to accessing and utilizing maternal healthcare services in South Sudan. BMC Health Serv Res [Internet]. 2018 Dec 9;18(1):10. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-017-2788-9>

75. Magadzire BP, Budden A, Ward K, Jeffery R, Sanders D. Frontline health workers as brokers: provider perceptions, experiences and mitigating strategies to improve access to essential medicines in South Africa. BMC Health Serv Res [Internet]. 2014 Dec 5;14(1):520. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-014-0520-6>

76. Kuwawenaruwa A, Wyss K, Wiedenmayer K, Metta E, Tediosi F. The effects of medicines availability and stock-outs on household’s utilization of healthcare

- services in Dodoma region, Tanzania. Health Policy Plan [Internet]. 2020 Apr 1;35(3):323–33. Available from: <https://academic.oup.com/heapol/article/35/3/323/5702177>
77. Oduro-Mensah E, Kwamie A, Antwi E, Amissah Bamfo S, Bainson HM, Marfo B, et al. Care Decision Making of Frontline Providers of Maternal and Newborn Health Services in the Greater Accra Region of Ghana. Leone T, editor. PLoS One [Internet]. 2013 Feb 13;8(2):e55610. Available from: <https://dx.plos.org/10.1371/journal.pone.0055610>
 78. Mathewos Oridanigo E, Beyene Salgado W, Gebissa Kebene F. Affordability of Essential Medicines and Associated Factors in Public Health Facilities of Jimma Zone, Southwest Ethiopia. Abdulah R, editor. Adv Pharmacol Pharm Sci [Internet]. 2021 Mar 16;2021:1–9. Available from: <https://www.hindawi.com/journals/aps/2021/6640133/>
 79. Obakiro SB, Kiyimba K, Napyo A, Kanyike AM, Mayoka WJ, Nnassozi AG, et al. Appropriateness and affordability of prescriptions to diabetic patients attending a tertiary hospital in Eastern Uganda: A retrospective cross-sectional study. PLoS One [Internet]. 2021;16(1):1–12. Available from: <http://dx.doi.org/10.1371/journal.pone.0245036>
 80. An SJ, George AS, LeFevre AE, Mpembeni R, Mosha I, Mohan D, et al. Supply-side dimensions and dynamics of integrating HIV testing and counselling into routine antenatal care: A facility assessment from Morogoro Region, Tanzania. BMC Health Serv Res [Internet]. 2015;15(451):1–15. Available from: <http://dx.doi.org/10.1186/s12913-015-1111-x>
 81. Boachie MK. Preferred Primary Healthcare Provider Choice Among Insured

- Persons in Ashanti Region, Ghana. *Int J Heal policy Manag* [Internet]. 2015 Oct 20;5(3):155–63. Available from: <https://pubmed.ncbi.nlm.nih.gov/26927586>
82. Karanja S, Gichuki R, Igunza P, Muhula S, Ofware P, Lesiamon J, et al. Factors influencing deliveries at health facilities in a rural Maasai Community in Magadi sub-County, Kenya. *BMC Pregnancy Childbirth* [Internet]. 2018 Dec 3;18(1):5. Available from: <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-017-1632-x>
 83. Kumsa A, Tura G, Nigussie A, Kebede G. Satisfaction with emergency obstetric and new born care services among clients using public health facilities in Jimma Zone, Oromia Regional State, Ethiopia; a cross sectional study. *BMC Pregnancy Childbirth* [Internet]. 2016;16(85):1–7. Available from: <http://dx.doi.org/10.1186/s12884-016-0877-0>
 84. Beyene D, Abuye H, Tilahun G. Effect of Auditable Pharmaceutical Services and Transaction System on Pharmaceutical Service Outcomes in Public Hospitals of SNNPR, Ethiopia. *Integr Pharm Res Pract* [Internet]. 2020 Oct;Volume 9:185–94. Available from: <https://www.dovepress.com/effect-of-auditable-pharmaceutical-services-and-transaction-system-on-peer-reviewed-article-IPRP>
 85. Mekonnen AB, Enquasselasie F. Patients’ preferences for attributes related to health care services at hospitals in Amhara Region, northern Ethiopia: a discrete choice experiment. *Patient Prefer Adherence* [Internet]. 2015 Sep;9:1293. Available from: <https://www.dovepress.com/patients-quo-preferences-for-attributes-related-to-health-care-servic-peer-reviewed-article->

PPA

86. Abiye Z, Tesfaye A, Hawaze S. Barriers to access: Availability and affordability of essential drugs in a retail outlet of a public health center in south western ethiopia. *J Appl Pharm Sci*. 2013;3(10):101–5.
87. Tadesse T, Abuye H, Tilahun G. Availability and affordability of children essential medicines in health facilities of southern nations, nationalities, and people region, Ethiopia: key determinants for access. *BMC Public Health* [Internet]. 2021 Dec 13;21(1):714. Available from: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10745-5>
88. Mackintosh M, Mujinja PGM. Markets and Policy Challenges in Access to Essential Medicines for Endemic Disease. *J Afr Econ* [Internet]. 2010 Nov 1;19(Supplement 3):iii166–200. Available from: <https://academic.oup.com/jae/article-lookup/doi/10.1093/jae/ejq017>
89. Onyango MA, Vian T, Hirsch I, Salvi DD, Laing R, Rockers PC, et al. Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study. Postma M, editor. *PLoS One* [Internet]. 2018 Aug 24;13(8):e0201917. Available from: <https://dx.plos.org/10.1371/journal.pone.0201917>
90. Sakyi EK, Atinga RA, Adzei FA. Managerial problems of hospitals under Ghana's National Health Insurance Scheme. *Clin Gov An Int J* [Internet]. 2012 Jul 27;17(3):178–90. Available from: <https://www.emerald.com/insight/content/doi/10.1108/14777271211251291/full/html>

91. Mwathi MW, Ben OO. Availability of essential medicines in public hospitals: A study of selected public hospitals in Nakuru County, Kenya. *African J Pharm Pharmacol* [Internet]. 2014 May 8;8(17):438–42. Available from: <http://academicjournals.org/journal/AJPP/article-abstract/1F1BA2444314>

92. Kuwawenaruwa A, Tediosi F, Obrist B, Metta E, Chiluda F, Wiedenmayer K, et al. The role of accountability in the performance of Jazia prime vendor system in Tanzania. *J Pharm Policy Pract*. 2020;13(25):1–13.

93. Perumal-Pillay VA, Suleman F. Selection of essential medicines for South Africa - An analysis of in-depth interviews with national essential medicines list committee members. *BMC Health Serv Res* [Internet]. 2017;17(17):1–17. Available from: <http://dx.doi.org/10.1186/s12913-016-1946-9>

94. Mkoka DA, Goicolea I, Kiwara A, Mwangi M, Hurtig A-K. Availability of drugs and medical supplies for emergency obstetric care: experience of health facility managers in a rural District of Tanzania. *BMC Pregnancy Childbirth* [Internet]. 2014 Dec 19;14(1):108. Available from: <http://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/1471-2393-14-108>

95. Muthathi IS, Levin J, Rispel LC. Decision space and participation of primary healthcare facility managers in the Ideal Clinic Realisation and Maintenance programme in two South African provinces. *Health Policy Plan* [Internet]. 2020 Apr 1;35(3):302–12. Available from: <https://academic.oup.com/heapol/article/35/3/302/5686168>

96. Ward CL, Guo MZ, Amukele TK, Abdul-Karim A, Schroeder LF. Availability and Prices of WHO Essential Diagnostics in Laboratories in West Africa: A

- Landscape Survey of Diagnostic Testing in Northern Ghana. J Appl Lab Med [Internet]. 2021 Jan 12;6(1):51–62. Available from: <https://academic.oup.com/jalm/article/6/1/51/6016498>
97. Ndagire E, Kawakatsu Y, Nalubwama H, Atala J, Sarnacki R, Pulle J, et al. Examining the ugandan health system's readiness to deliver rheumatic heart disease-related services. PLoS Negl Trop Dis [Internet]. 2021;15(2):1–16. Available from: <http://dx.doi.org/10.1371/journal.pntd.0009164>
 98. Jessen N, Ferrer JM, Mocumbi AO, Boladuadua S, Jones J, Auala T, et al. PO376 Measuring Access to Essential CVD Medicines and Diagnostics in Maputo City, Mozambique. Glob Heart. 2018 Dec;13(4):458.
 99. Horton S, Fleming KA, Kuti M, Looi L-M, Pai SA, Sayed S, et al. The Top 25 Laboratory Tests by Volume and Revenue in Five Different Countries. Am J Clin Pathol [Internet]. 2019 Apr 2;151(5):446–51. Available from: <https://academic.oup.com/ajcp/article/151/5/446/5237639>
 100. Bay N, Juga E, Macuacua C, João J, Costa M, Stewart S, et al. Assessment of care provision for hypertension at the emergency Department of an Urban Hospital in Mozambique. BMC Health Serv Res [Internet]. 2019 Dec 18;19(1):975. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-019-4820-8>
 101. Wahlfeld CC, Muicha A, Harrison P, Kipp AM, Claquin G, Silva WP, et al. HIV Rapid Diagnostic Test Inventories in Zambézia Province, Mozambique: A Tale of 2 Test Kits. Int J Heal Policy Manag [Internet]. 2019 Feb 26;8(5):292–9. Available from: http://www.ijhpm.com/article_3597.html

102. Rawlins B, Plotkin M, Rakotovao JP, Getachew A, Vaz M, Ricca J, et al. Screening and management of pre-eclampsia and eclampsia in antenatal and labor and delivery services: findings from cross-sectional observation studies in six sub-Saharan African countries. BMC Pregnancy Childbirth [Internet]. 2018 Dec 23;18(1):346. Available from: <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-018-1972-1>
103. Tickell KD, Mangale DI, Tornberg-Belanger SN, Bourdon C, Thitiri J, Timbwa M, et al. A mixed method multi-country assessment of barriers to implementing pediatric inpatient care guidelines. Gurgel RQ, editor. PLoS One [Internet]. 2019 Mar 25;14(3):e0212395. Available from: <https://dx.plos.org/10.1371/journal.pone.0212395>
104. Perumal-Pillay VA, Suleman F. Parents' and guardians' perceptions on availability and pricing of medicines and healthcare for children in eThekweni, South Africa – a qualitative study. BMC Health Serv Res [Internet]. 2017 Dec 19;17(1):417. Available from: <http://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-017-2385-y>
105. Kefale AT, Shebo HH. Availability of essential medicines and pharmaceutical inventory management practice at health centers of Adama town, Ethiopia. BMC Health Serv Res [Internet]. 2019 Dec 25;19(1):254. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-019-4087-0>
106. Lonnée HA, Madzimbamuto F, Erlandsen ORM, Vassenden A, Chikumba E,

- Dimba R, et al. Anesthesia for Cesarean Delivery. Anesth Analg [Internet]. 2018 Jun;126(6):2056–64. Available from: <http://journals.lww.com/00000539-201806000-00040>
107. Loveday M, Scott V, McLoughlin J, Amien F, Zweigenthal V. Assessing care for patients with TB/HIV/STI infections in a rural district in Kwazulu-Natal. South African Med J. 2011;101(12):887–90.
108. Orubu ESF, Robert FO, Samuel M, Megbule D. Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria. Health Policy Plan [Internet]. 2019 Dec 1;34(Supplement_3):iii20–6. Available from: https://academic.oup.com/heapol/article/34/Supplement_3/iii20/5670625
109. Saiyoki LL, Rose O, Aggrey O. Accessibility of essential medicines for non-communicable diseases in a devolved system of government in trans nzoia County, Kenya. Int J Dev Res. 2019;09(11):31586–90.
110. Martei YM, Chiyapo S, Grover S, Ramogola-Masire D, Dryden-Peterson S, Shulman LN, et al. Availability of WHO Essential Medicines for Cancer Treatment in Botswana. J Glob Oncol [Internet]. 2018 Dec;2018(4):1–8. Available from: <https://ascopubs.org/doi/10.1200/JGO.17.00063>
111. Demessie MB, Workneh BD, Mohammed SA, Hailu AD. Availability of Tracer Drugs and Implementation of Their Logistic Management Information System in Public Health Facilities of Dessie, North-East Ethiopia. Integr Pharm Res Pract [Internet]. 2020 Aug;Volume 9:83–92. Available from: <https://www.dovepress.com/availability-of-tracer-drugs-and-implementation-of-their-logistic-mana-peer-reviewed-article-IPRP>

112. Obiechina G, Ekenedo G. Factors affecting utilization of University health services in a tertiary institution in South-West Nigeria. *Niger J Clin Pract* [Internet]. 2013;16(4):454. Available from: <http://www.njcponline.com/text.asp?2013/16/4/454/116888>
113. Isadru VR, Nanyonga RC, Alege JB. Health Facilities' Readiness to Manage Hypertension and Diabetes Cases at Primary Health Facilities in Bidibidi Refugee Settlement, Yumbe District, Uganda. J. Gonzalez J-P, editor. *J Trop Med* [Internet]. 2021 Jan 22;2021:1–10. Available from: <https://www.hindawi.com/journals/jtm/2021/1415794/>
114. Elnour FA, Alagib MEA, Bansal D, Farag EABA, Malik EM. Severe malaria management: Current situation, challenges and lessons learned from Gezira State, Sudan. *Malar J* [Internet]. 2019;18(1):1–8. Available from: <https://doi.org/10.1186/s12936-019-2805-z>
115. Rogers HE, Akiteng AR, Mutungi G, Ettinger AS, Schwartz JI. Capacity of Ugandan public sector health facilities to prevent and control non-communicable diseases: an assessment based upon WHO-PEN standards. *BMC Health Serv Res* [Internet]. 2018 Dec 6;18(1):606. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-018-3426-x>
116. Lonnée HA, Taule K, Knoph Sandvand J, Koroma MM, Dumbuya A, Jusu KSK, et al. A survey of anaesthesia practices at all hospitals performing caesarean sections in Sierra Leone. *Acta Anaesthesiol Scand* [Internet]. 2021 Mar 5;65(3):404–19. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/aas.13736>

117. Wirtz VJ, Turpin K, Laing RO, Mukiira CK, Rockers PC. Access to medicines for asthma, diabetes and hypertension in eight counties of Kenya. *Trop Med Int Heal* [Internet]. 2018 Aug;23(8):879–85. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/tmi.13081>
118. Mutale W, Bosomprah S, Shankalala P, Mweemba O, Chilengi R, Kapambwe S, et al. Assessing capacity and readiness to manage NCDs in primary care setting: Gaps and opportunities based on adapted WHO PEN tool in Zambia. Moise IK, editor. *PLoS One* [Internet]. 2018 Aug 23;13(8):e0200994. Available from: <https://dx.plos.org/10.1371/journal.pone.0200994>
119. Bekele A, Getachew T, Amenu K, Defar A, Teklie H, Gelibo T, et al. Service availability and readiness for diabetes care at health facilities in Ethiopia. *Ethiop J Heal Dev*. 2017;31(2):110–9.
120. Kabunga LN, Mujasi P. Does access to credit services influence availability of essential child medicines and licensing status among private medicine retail outlets in Uganda? *J Pharm Policy Pract* [Internet]. 2017 Dec 21;10(1):30. Available from: <http://joppp.biomedcentral.com/articles/10.1186/s40545-017-0116-8>
121. Legesse H, Seyoum H, Abdo A, Ameha A, Abdulber S, Sylla M, et al. Supply chain management for community-based newborn care in rural Ethiopia: Challenges, strategies implemented and recommendations. *Ethiop Med J*. 2019;57(3):247–53.
122. Kamuhabwa AAR, Twaha K. Availability and affordability of essential antibiotics for pediatrics in semi-rural areas in Tanzania. *Int J Pharm Sci Res* [Internet]. 2014;7(2):587–600. Available from: <http://dx.doi.org/10.1186/s12887-016-0572->

123. Aryeetey GC, Nonvignon J, Amissah C, Buckle G, Aikins M. The effect of the National Health Insurance Scheme (NHIS) on health service delivery in mission facilities in Ghana: A retrospective study. *Global Health* [Internet]. 2016;12(32):1–9. Available from: <http://dx.doi.org/10.1186/s12992-016-0171-y>
124. Gutema G, Engidawork E. Affordability of commonly prescribed antibiotics in a large tertiary teaching hospital in Ethiopia: A challenge for the national drug policy objective. *BMC Res Notes* [Internet]. 2018;11(925):1–6. Available from: <https://doi.org/10.1186/s13104-018-4021-2>
125. Okech UK, Chokwe T, Mung'Ayi V. The operational setup of intensive care units in a low income country in east africa. *East Afr Med J*. 2015;92(2):72–80.
126. Auwal F, Dahiru MN, Abdu-Aguye SN. Availability and rationality of fixed dose combinations available in Kaduna, Nigeria. *Pharm Pract (Granada)* [Internet]. 2019 Jun 30;17(2):1470. Available from: <https://www.pharmacypractice.org/index.php/pp/article/view/1470>
127. Mhlenga BS, Suleman F. Price, availability and affordability of medicines. *African J Prim Heal Care Fam Med* [Internet]. 2014 Jun 24;6(1):1–6. Available from: <https://phcfm.org/index.php/phcfm/article/view/604>
128. Mujinja PGM, Mackintosh M, Justin-Temu M, Wuyts M. Local production of pharmaceuticals in Africa and access to essential medicines: 'urban bias' in access to imported medicines in Tanzania and its policy implications. *Global Health* [Internet]. 2014 Dec 10;10(1):12. Available from: <https://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603->

10-12

129. Mbonyinshuti F, Takarinda KC, Manzi M, Iradukunda PG, Kabatende J, Habiyaemye T, et al. Public Health Action Campaign. Public Heal Action [Internet]. 2021;11(1):5–11. Available from: <http://dx.doi.org/10.5588/pha.16.0125%0ASetting>:
130. Mathewos B, Musema Y, Bekele A, Yeshanew B, Tadele G, Teferi E, et al. Community-based newborn care in Ethiopia: Implementation strength and lessons learned. *Ethiop Med J*. 2019;57(3):269–79.
131. Olubumni M O, Maria S M, Jabu M. Nurses' Perceptions About Stock-outs of Essential Medicines at Primary Health Care Facilities in Vhembe District, South Africa. *Open Public Health J* [Internet]. 2019 Dec 31;12(1):550–7. Available from: <https://openpublichealthjournal.com/VOLUME/12/PAGE/550/>
132. Khuluza F, Haefele-Abah C. The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study. Thet Wai K, editor. *PLoS One* [Internet]. 2019 Feb 12;14(2):e0212125. Available from: <https://dx.plos.org/10.1371/journal.pone.0212125>
133. Khuluza F, Heide L. Availability and affordability of antimalarial and antibiotic medicines in Malawi. Postma M, editor. *PLoS One* [Internet]. 2017 Apr 18;12(4):e0175399. Available from: <https://dx.plos.org/10.1371/journal.pone.0175399>
134. Lyon CB, Merchant AI, Schwalbach T, Pinto EF V., Jeque EC, McQueen KAK. Anesthetic Care in Mozambique. *Anesth Analg* [Internet]. 2016 May;122(5):1634–9. Available from: <http://journals.lww.com/00000539->

201605000-00053

135. Crowley T, Stellenberg EL. An evaluation of the adequacy of pharmaceutical services for the provision of antiretroviral treatment in primary health care clinics. Heal SA Gesondheid [Internet]. 2015;20(1):83–90. Available from: <http://dx.doi.org/10.1016/j.hsag.2015.02.004>
136. Jingi AM, Noubiap JJN, Ewane Onana A, Nansseu JRN, Wang B, Kingue S, et al. Access to Diagnostic Tests and Essential Medicines for Cardiovascular Diseases and Diabetes Care: Cost, Availability and Affordability in the West Region of Cameroon. Reboldi G, editor. PLoS One [Internet]. 2014 Nov 4;9(11):e111812. Available from: <https://dx.plos.org/10.1371/journal.pone.0111812>
137. Ogunkunle O, Olanrewaju D, Oyinlade O. An evaluation of school health services in Sagamu, Nigeria. Niger J Clin Pract [Internet]. 2014;17(3):336. Available from: <http://www.njcponline.com/text.asp?2014/17/3/336/130236>
138. Orji IA, Baldrige AS, Omitiran K, Guo M, Ajisegiri WS, Ojo TM, et al. Capacity and site readiness for hypertension control program implementation in the Federal Capital Territory of Nigeria: a cross-sectional study. BMC Health Serv Res [Internet]. 2021 Dec 9;21(1):322. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-021-06320-8>
139. Shiferaw F, Letebo M, Misganaw A, Feleke Y, Gelibo T, Getachew T, et al. Non-communicable Diseases in Ethiopia: Disease burden, gaps in health care delivery and strategic directions. Ethiop J Heal Dev. 2018;32(3).

140. Armstrong-Hough M, Sharma S, Kishore SP, Akiteng AR, Schwartz JI. Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: A descriptive time series analysis. PLoS One [Internet]. 2020;15(12 December):1–8. Available from: <http://dx.doi.org/10.1371/journal.pone.0241555>
141. Kaiser AH, Hehman L, Forsberg BC, Simangolwa WM, Sundewall J. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia. Thet Wai K, editor. PLoS One [Internet]. 2019 Dec 13;14(12):e0226169. Available from: <https://dx.plos.org/10.1371/journal.pone.0226169>
142. Perumal-Pillay VA, Suleman F. Understanding the decision making process of selection of medicines in the private sector in South Africa – lessons for low-middle income countries. J Pharm Policy Pract [Internet]. 2020 Dec 21;13(1):17. Available from: <https://joppp.biomedcentral.com/articles/10.1186/s40545-020-00223-5>
143. Birabwa C, Bwambale MF, Waiswa P, Mayega RW. Quality and barriers of outpatient diabetes care in rural health facilities in Uganda – a mixed methods study. BMC Health Serv Res [Internet]. 2019 Dec 16;19(1):706. Available from: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-019-4535-x>
144. Emmanuel Awucha N, Chinelo JaneFrances O, Chima Meshach A, Chiamaka Henrietta J, Ibilolia Daniel A, Esther Chidiebere N. Impact of the COVID-19 Pandemic on Consumers' Access to Essential Medicines in Nigeria. Am J Trop Med Hyg [Internet]. 2020 Oct 7;103(4):1630–4. Available from:

<https://ajtmh.org/doi/10.4269/ajtmh.20-0838>

145. Ashigbie PG, Rockers PC, Laing RO, Cabral HJ, Onyango MA, Buleti JPL, et al. Availability and prices of medicines for non-communicable diseases at health facilities and retail drug outlets in Kenya: a cross-sectional survey in eight counties. *BMJ Open* [Internet]. 2020 May 15;10(5):e035132. Available from: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-035132>
146. Ooms GI, Klatser P, van den Ham HA, Reed T. Barriers to Accessing Internationally Controlled Essential Medicines in Uganda: A Qualitative Study. *J Pain Symptom Manage* [Internet]. 2019;58(5):835–43. Available from: <https://doi.org/10.1016/j.jpainsymman.2019.07.002>
147. Sado E, Sufa A. Availability and affordability of essential medicines for children in the Western part of Ethiopia: Implication for access. *BMC Pediatr* [Internet]. 2016;16(40):1–8. Available from: <http://dx.doi.org/10.1186/s12887-016-0572-3>
148. Bizimana T, Kayumba PC, Heide L. Prices, availability and affordability of medicines in Rwanda. *PLoS One* [Internet]. 2020;15(8 August):1–14. Available from: <http://dx.doi.org/10.1371/journal.pone.0236411>
149. Saouadogo H, Compaore M. Essential medicines access survey in public hospitals of Burkina Faso. *African J Pharm Pharmacol*. 2010;4(6):373–80.
150. Exley J, Pitchforth E, Okeke E, Glick P, Abubakar IS, Chari A, et al. Persistent barriers to care; a qualitative study to understand women’s experiences in areas served by the midwives service scheme in Nigeria. *BMC Pregnancy Childbirth* [Internet]. 2016;16(232):1–10. Available from: <http://dx.doi.org/10.1186/s12884-016-1026-5>

151. Armstrong-Hough M, Kishore SP, Byakika S, Mutungi G, Nunez-Smith M, Schwartz JI. Disparities in availability of essential medicines to treat non-communicable diseases in Uganda: A Poisson analysis using the Service Availability and Readiness Assessment. Khan HTA, editor. PLoS One [Internet]. 2018 Feb 8;13(2):e0192332. Available from: <https://dx.plos.org/10.1371/journal.pone.0192332>

152. Saksena P, Reyburn H, Njau B, Chonya S, Mbakilwa H, Mills A. Patient costs for paediatric hospital admissions in Tanzania: a neglected burden? Health Policy Plan [Internet]. 2010 Jul 1;25(4):328–33. Available from: <https://academic.oup.com/heapol/article-lookup/doi/10.1093/heapol/czq003>

153. Nsabagasani X, Ogwal-Okeng J, Hansen EH, Mbonye A, Muyinda H, Ssengooba F. ‘Better medicines for children’ within the Integrated Management of Childhood Illness framework: A qualitative inquiry in Uganda. J Pharm Policy Pract [Internet]. 2016;9(22):1–16. Available from: <http://dx.doi.org/10.1186/s40545-016-0071-9>

154. Epiu I, Wabule A, Kambugu A, Mayanja-Kizza H, Tindimwebwa JVB, Dubowitz G. Key bottlenecks to the provision of safe obstetric anaesthesia in low- income countries; a cross-sectional survey of 64 hospitals in Uganda. BMC Pregnancy Childbirth [Internet]. 2017 Dec 17;17(1):387. Available from: <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-017-1566-3>

155. Wood-Thompson DK, Enyuma COA, Laher AE. Procedural sedation and analgesia practices in the emergency centre. African J Emerg Med [Internet]. 2019;9(1):1–6. Available from: <https://doi.org/10.1016/j.afjem.2018.09.003>

156. Gilroy KE, Callaghan-Koru JA, Cardemil C V., Nsona H, Amouzou A, Mtimuni A, et al. Quality of sick child care delivered by Health Surveillance Assistants in Malawi. *Health Policy Plan* [Internet]. 2013 Sep 1;28(6):573–85. Available from: <https://academic.oup.com/heapol/article-lookup/doi/10.1093/heapol/czs095>
157. Alissa EM, Ferns GA. Dietary Fruits and Vegetables and Cardiovascular Diseases Risk. *Crit Rev Food Sci Nutr* [Internet]. 2017 Jul 20;57(9):1950–62. Available from: <http://www.tandfonline.com/doi/full/10.1080/10408398.2015.1040487>
158. Ngcobo NJ, Kamupira MG. The status of vaccine availability and associated factors in Tshwane government clinics. *South African Med J* [Internet]. 2017 May 24;107(6):535. Available from: <http://www.samj.org.za/index.php/samj/article/view/11914>
159. Chukwu OA, Chukwu U, Lemoha C. Poor performance of medicines logistics and supply chain systems in a developing country context: lessons from Nigeria. *J Pharm Heal Serv Res* [Internet]. 2018 Dec;9(4):289–91. Available from: <https://academic.oup.com/jphsr/article/9/4/289-291/6068323>
160. Magadzire BP, Ward K, Leng HMJ, Sanders D. Inefficient procurement processes undermine access to medicines in the Western Cape Province of South Africa. *South African Med J* [Internet]. 2017 Jun 30;107(7):581. Available from: <http://www.samj.org.za/index.php/samj/article/view/11937>
161. Wagenaar BH, Gimbel S, Hoek R, Pfeiffer J, Michel C, Manuel JL, et al. Stock-outs of essential health products in Mozambique - longitudinal analyses from 2011 to 2013. *Trop Med Int Heal* [Internet]. 2014 Jul;19(7):791–801. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/tmi.12314>

162. Mukundiyukuri JP, Irakiza JJ, Nyirahabimana N, Ng'ang'a L, Park PH, Ngoga G, et al. Availability, Costs and Stock-Outs of Essential NCD Drugs in Three Rural Rwandan Districts. *Ann Glob Heal* [Internet]. 2020 Sep 25;86(1):1–15. Available from: <https://annalsofglobalhealth.org/articles/10.5334/aogh.2729/>
163. Kusemererwa D, Alban A, Obua OT, Trap B. An exploratory study on equity in funding allocation for essential medicines and health supplies in Uganda's public sector. *BMC Health Serv Res* [Internet]. 2016;16(453):1–10. Available from: <http://dx.doi.org/10.1186/s12913-016-1698-6>
164. Bravo MP, Peratikos MB, Muicha AS, Mahagaja E, Alvim MFS, Green AF, et al. Monitoring Pharmacy and Test Kit Stocks in Rural Mozambique: U.S. President's Emergency Plan for AIDS Relief Surveillance to Help Prevent Ministry of Health Shortages. *AIDS Res Hum Retroviruses* [Internet]. 2020 May 1;36(5):415–26. Available from: <https://www.liebertpub.com/doi/10.1089/aid.2019.0057>
165. Webb EM, Rheeder P, Wolvaardt JE. The ability of primary healthcare clinics to provide quality diabetes care: An audit. *African J Prim Heal Care Fam Med* [Internet]. 2019 Oct 17;11(1):1–6. Available from: <http://www.phcfm.org/index.php/PHCFM/article/view/2094>
166. Surgey G, Chalkidou K, Reuben W, Suleman F, Miot J, Hofman K. Introducing health technology assessment in Tanzania. *Int J Technol Assess Health Care* [Internet]. 2020 Apr 12;36(2):80–6. Available from: https://www.cambridge.org/core/product/identifier/S0266462319000588/type/journal_article
167. Coghlan R, Stephens P, Mwale B, Siyanga M. A new approach to gathering pharmaceutical market data to support policy implementation and access to

- medicines: As demonstrated by malaria medicines in Zambia. *Malar J* [Internet]. 2018;17(444):1–14. Available from: <https://doi.org/10.1186/s12936-018-2594-9>
168. Koroma MM, Kamara MA, Keita N, Lokossou VK, Sundufu AJ, Jacobsen KH. Access to Essential Medications and Equipment for Obstetric and Neonatal Primary Care in Bombali District, Sierra Leone. *World Med Heal Policy* [Internet]. 2019 Mar 20;11(1):8–23. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/wmh3.295>
 169. Solnes Miltenburg A, Kiritta RF, Bishanga TB, van Roosmalen J, Stekelenburg J. Assessing emergency obstetric and newborn care: can performance indicators capture health system weaknesses? *BMC Pregnancy Childbirth* [Internet]. 2017 Dec 20;17(1):92. Available from: <http://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-017-1282-z>
 170. Brhlikova P, Maigetter K, Murison J, Agaba AG, Tusiimire J, Pollock AM. Registration and local production of essential medicines in Uganda. *J Pharm Policy Pract* [Internet]. 2020 Dec 11;13(1):31. Available from: <https://joppp.biomedcentral.com/articles/10.1186/s40545-020-00234-2>
 171. Nnebue C, Ebenebe U, Adogu P, Adinma E, Ifeadike C, Nwabueze A. Adequacy of resources for provision of maternal health services at the primary health care level in Nnewi, Nigeria. *Niger Med J* [Internet]. 2014;55(3):235. Available from: <http://www.nigeriamedj.com/text.asp?2014/55/3/235/132056>
 172. Lukama L, Kalinda C, Kuhn W, Aldous C. Availability of ENT Surgical Procedures and Medication in Low-Income Nation Hospitals: Cause for Concern in Zambia. *Biomed Res Int* [Internet]. 2020 Mar 24;2020:1–8. Available from:

<https://www.hindawi.com/journals/bmri/2020/1980123/>

173. Niankara I. The Relative Influence of Generic Essential Drugs and Nursing Staff Supplies on Access to Primary Healthcare Services in Burkina Faso: A Trivariate Probit Modeling Approach. 2018;(February):1–25.
174. Dzudie A, Njume E, Abanda M, Aminde L, Hamadou B, Dzekem B, et al. Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study. PLoS One [Internet]. 2020;15(3):1–12. Available from: <http://dx.doi.org/10.1371/journal.pone.0229307>
175. Koduah A, Asare BA, Gavor E, Gyansa-Lutterodt M, Andrews Annan E, Ofei FW. Use of evidence and negotiation in the review of national standard treatment guidelines and essential medicines list: experience from Ghana. Health Policy Plan [Internet]. 2019 Nov 1;34(Supplement_2):ii104–20. Available from: https://academic.oup.com/heapol/article/34/Supplement_2/ii104/5625032
176. Orubu ESF, Okwelogu C, Opanuga O, Nunn T, Tuleu C. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development. Health Policy Plan [Internet]. 2016 Sep 1;czw115. Available from: <https://academic.oup.com/heapol/article-lookup/doi/10.1093/heapol/czw115>
177. Kahn R, Bangura S, Hann K, Salvi A, Gassimu J, Kabba A, et al. Strengthening provision of essential medicines to women and children in post-Ebola Sierra Leone. J Glob Health [Internet]. 2019 Jun;9(1):1–5. Available from: <http://jogh.org/documents/issue201901/jogh-09-010307.pdf>

178. Mikkelsen-Lopez I, Cowley P, Kasale H, Mbuya C, Reid G, de Savigny D. Essential medicines in Tanzania: does the new delivery system improve supply and accountability? Heal Syst (Basingstoke, England) [Internet]. 2013/11/15. 2014 Feb;3(1):74–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/25013720>
179. Bintabara D, Ernest A, Mpondo B. Health facility service availability and readiness to provide basic emergency obstetric and newborn care in a low-resource setting: evidence from a Tanzania National Survey. BMJ Open [Internet]. 2019 Feb;9(2):e020608. Available from: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2017-020608>
180. Kirua RB, Temu MJ, Mori AT. Prices of medicines for the management of pain, diabetes and cardiovascular diseases in private pharmacies and the national health insurance in Tanzania. Int J Equity Health [Internet]. 2020 Dec 10;19(1):203. Available from: <https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-020-01319-9>
181. Hunie M, Desse T, Fenta E, Teshome D, Gelaw M, Gashaw A. Availability of Emergency Drugs and Essential Equipment in Intensive Care Units in Hospitals of Ethiopia: A Multicenter Cross-Sectional Study. Open Access Emerg Med [Internet]. 2020 Dec;Volume 12:435–40. Available from: <https://www.dovepress.com/availability-of-emergency-drugs-and-essential-equipment-in-intensive-c-peer-reviewed-article-OAEM>
182. Anselmi L, Binyaruka P, Borghi J. Understanding causal pathways within health systems policy evaluation through mediation analysis: an application to payment for performance (P4P) in Tanzania. Implement Sci [Internet]. 2017 Dec

2;12(1):10. Available from:
<http://implementationscience.biomedcentral.com/articles/10.1186/s13012-016-0540-1>

183. Sieleunou I, De Allegri M, Roland Enok Bonong P, Ouédraogo S, Ridde V. Does performance-based financing curb stock-outs of essential medicines? Results from a randomised controlled trial in Cameroon. Trop Med Int Heal [Internet]. 2020 Aug 16;25(8):944–61. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/tmi.13447>
184. Sieleunou I, Turcotte-Tremblay A-M, De Allegri M, Taptué Fotso J-C, Azinyui Yumo H, Magne Tamga D, et al. How does performance-based financing affect the availability of essential medicines in Cameroon? A qualitative study. Health Policy Plan [Internet]. 2019 Dec 1;34(Supplement_3):iii4–19. Available from: https://academic.oup.com/heapol/article/34/Supplement_3/iii4/5670620
185. Birabwa C, Murison J, Evans V, Obua C, Agaba A, Waako P, et al. The availability of six tracer medicines in private medicine outlets in Uganda. J Pharm Policy Pract [Internet]. 2014 Dec 8;7(1):18. Available from: <https://joppp.biomedcentral.com/articles/10.1186/s40545-014-0018-y>
186. Wagenaar BH, Stergachis A, Rao D, Hoek R, Cumbe V, Napúa M, et al. The availability of essential medicines for mental healthcare in Sofala, Mozambique. Glob Health Action [Internet]. 2015 Dec 15;8(1):27942. Available from: <https://www.tandfonline.com/doi/full/10.3402/gha.v8.27942>
187. Feikin DR, Slutsker L, Adazu K, Hamel MJ, Sewe M, Williamson JM, et al. A Reversal in Reductions of Child Mortality in Western Kenya, 2003–2009. Am J Trop Med Hyg [Internet]. 2011 Oct 1;85(4):597–605. Available from:

<https://ajtmh.org/doi/10.4269/ajtmh.2011.10-0678>

188. Maïga D, Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health Policy (New York) [Internet]. 2010 Oct;97(2–3):130–5. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016885101000103X>
189. Busetto L, Wick W, Gumbinger C. How to use and assess qualitative research methods. Neurol Res Pract [Internet]. 2020;2(1):14. Available from: <https://doi.org/10.1186/s42466-020-00059-z>
190. Miller CJ, Smith SN, Pugatch M. Experimental and quasi-experimental designs in implementation research. Psychiatry Res [Internet]. 2020;283:112452. Available from: <https://www.sciencedirect.com/science/article/pii/S0165178119306833>
191. Peacocke EF, Myhre SL, Foss HS, Gopinathan U. National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis. PLOS Med [Internet]. 2022 Mar 11;19(3):e1003944. Available from: <https://doi.org/10.1371/journal.pmed.1003944>
192. Kane J, Landes M, Carroll C, Nolen A, Sodhi S. A systematic review of primary care models for non-communicable disease interventions in Sub-Saharan Africa. BMC Fam Pract [Internet]. 2017;18(1):46. Available from: <https://doi.org/10.1186/s12875-017-0613-5>
193. Bollyky TJ, Templin T, Cohen M, Dieleman JL. Lower-Income Countries That Face The Most Rapid Shift In Noncommunicable Disease Burden Are Also The Least Prepared. Health Aff [Internet]. 2017 Nov 1;36(11):1866–75. Available

from: <https://doi.org/10.1377/hlthaff.2017.0708>

194. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. The COVID-19 pandemic and healthcare systems in Africa: a scoping review of preparedness, impact and response. *BMJ Glob Heal* [Internet]. 2021 Dec 1;6(12):e007179. Available from: <https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2021-007179>
195. World Health Organization. Evidence synthesis for health policy and systems: a methods guide [Internet]. Langlois EV, Daniels K AE, editor. Geneva: World Health Organization; 2018. Available from: <https://apps.who.int/iris/handle/10665/275367>
196. World Health Organisation (WHO). Selection of essential in vitro diagnostics at country level using the WHO Model List of Essential In Vitro Diagnostics to develop and update a national list of essential in vitro diagnostics. [Internet]. Geneva: World Health Organization; 2021. Available from: <https://www.who.int/publications/i/item/9789240030923>
197. World Health Organisation (WHO). WHO publishes new Essential Diagnostics List and urges countries to prioritize investments in testing [Internet]. 2021. Available from: <https://www.who.int/news/item/29-01-2021-who-publishes-new-essential-diagnostics-list-and-urges-countries-to-prioritize-investments-in-testing>
198. World Health Organisation (WHO). Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies [Internet]. Geneva; 2010. Available from: <https://apps.who.int/iris/handle/10665/258734>

199. Horton S, Camacho Rodriguez R, Anderson BO, Aung S, Awuah B, Delgado Pebé L, et al. Health system strengthening: Integration of breast cancer care for improved outcomes. *Cancer* [Internet]. 2020 May 15;126 Suppl(Suppl 10):2353–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/32348567>
200. Agodokpessi G, Aït-Khaled N, Gninafon M, Tawo L, Bekou W, Perrin C, et al. Assessment of a revolving drug fund for essential asthma medicines in Benin. *J Pharm Policy Pract* [Internet]. 2015 Dec 13;8(1):12. Available from: <https://joppp.biomedcentral.com/articles/10.1186/s40545-015-0033-7>
201. Manji I, Manyara SM, Jakait B, Ogallo W, Hagedorn IC, Lukas S, et al. The Revolving Fund Pharmacy Model: backing up the Ministry of Health supply chain in western Kenya. *Int J Pharm Pract* [Internet]. 2016 Sep 13;24(5):358–66. Available from: <https://academic.oup.com/ijpp/article/24/5/358/6100499>
202. Biermann O, Atkins S, Lönnroth K, Caws M, Viney K. ‘Power plays plus push’: experts’ insights into the development and implementation of active tuberculosis case-finding policies globally, a qualitative study. *BMJ Open* [Internet]. 2020 Jun 3;10(6):e036285. Available from: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-036285>
203. Keith RE, Crosson JC, O’Malley AS, Crompton D, Taylor EF. Using the Consolidated Framework for Implementation Research (CFIR) to produce actionable findings: a rapid-cycle evaluation approach to improving implementation. *Implement Sci* [Internet]. 2017;12(1):15. Available from: <https://doi.org/10.1186/s13012-017-0550-7>
204. King DK, Shoup JA, Raebel MA, Anderson CB, Wagner NM, Ritzwoller DP, et al. Planning for Implementation Success Using RE-AIM and CFIR Frameworks:

- A Qualitative Study. *Front Public Heal* [Internet]. 2020;8. Available from: <https://www.frontiersin.org/article/10.3389/fpubh.2020.00059>
205. Shaw RB, Sweet SN, McBride CB, Adair WK, Martin Ginis KA. Operationalizing the reach, effectiveness, adoption, implementation, maintenance (RE-AIM) framework to evaluate the collective impact of autonomous community programs that promote health and well-being. *BMC Public Health* [Internet]. 2019;19(1):803. Available from: <https://doi.org/10.1186/s12889-019-7131-4>
 206. McCreight MS, Rabin BA, Glasgow RE, Ayele RA, Leonard CA, Gilmartin HM, et al. Using the Practical, Robust Implementation and Sustainability Model (PRISM) to qualitatively assess multilevel contextual factors to help plan, implement, evaluate, and disseminate health services programs. *Transl Behav Med* [Internet]. 2019 Nov 25;9(6):1002–11. Available from: <https://doi.org/10.1093/tbm/ibz085>
 207. Liles EG, Schneider JL, Feldstein AC, Mosen DM, Perrin N, Rosales AG, et al. Implementation challenges and successes of a population-based colorectal cancer screening program: a qualitative study of stakeholder perspectives. *Implement Sci* [Internet]. 2015;10(1):41. Available from: <https://doi.org/10.1186/s13012-015-0227-z>

Supporting information

S1 Appendix. Deviations from protocol.

S2 Appendix. Search strategy and SURE framework checklist.

S3 Appendix. Summary of included studies.

S1 Checklist. PRISMA-ScR checklist.

S1 Table. Barriers to the implementation of an essential diagnostic and medicines list.

S2 Table. Enablers for the implementation of an essential diagnostic and medicines list.
